

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
23 October 2003 (23.10.2003)

PCT

(10) International Publication Number  
WO 03/087346 A1

(51) International Patent Classification<sup>7</sup>: C12N 5/00

(21) International Application Number: PCT/NZ03/00059

(22) International Filing Date: 7 April 2003 (07.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
518163 5 April 2002 (05.04.2002) NZ

(71) Applicant (for all designated States except US): KIWI INGENUITY LIMITED [NZ/NZ]; 47 Gosford Drive, Howick, Auckland (NZ).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BLAKE, Deborah, Adella [NZ/NZ]; 38 Ara Kotinga Road, Manurewa Road, Auckland (NZ). CARTER, Nicola, Lewell [NZ/NZ]; 34 Glendowie Road, Glendowie, Auckland (NZ). HENRY, Stephen, Michael [NZ/NZ]; 47 Gosford Drive, Howick, Auckland (NZ).

(74) Agent: BALDWIN SHELSTON WATERS; 342 Lambton Quay, PO Box 582, 6004 Wellington (NZ).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/087346 A1

(54) Title: EMBRYO MODIFICATION AND IMPLANTATION

(57) Abstract: The present invention relates to constructs and methods used to enhance the attachment and implantation of an embryo. It is shown that modified glycolipids and glycolipid-attachment molecule constructs can be used to modify embryos, or localised to target tissues, to enhance interaction between the embryo and the target tissue, (typically the endometrium). The invention may advantageously be used to enhance implantation of embryos in the uterus, for example, in IVF treatments.

## EMBRYO MODIFICATION AND IMPLANTATION

This invention relates to constructs and methods used to enhance the implantation of an embryo into the uterus. In particular, the invention relates to 5 modified embryos which have been modified by the insertion into the cell membrane (or zona pellucida) of the embryo of constructs which have a binding affinity for mucus or cell membrane surfaces, or enhance cellular interactions.

### BACKGROUND

10

Each year 15% of couples seek medical advice because of difficulties becoming pregnant (WHO 1997). Sub-fertility is therefore currently one of the most frequent health concerns facing the population aged 25-45 years. For the past two decades, *in vitro* fertilisation (IVF) has provided an effective form of 15 assistance for a large proportion of these couples. Indeed, IVF now accounts for 1.3% of all live births in Europe (Nygren *et al.* 2001) and 1.7% of all live births in Australasia (Hurst *et al.* 2001).

From the inception of routine IVF in 1978, pregnancy rates have risen steadily to 20 levels considered normal for the fertile population (approximately 25% per attempt). The quest to break through this physiological barrier is driven by the significant financial and emotional cost for each IVF treatment for individuals.

Failure of embryos to implant into the lining of the uterus (endometrium) during 25 an IVF treatment cycle is widely accepted by health professionals as the most significant limiting factor to improving success rates. The scale of embryo wastage following transfer into IVF patients is enormous, such that 80-85% of embryos fail to result in a pregnancy (Blake *et al.* 2002). Recent analysis of daily urine levels of human chronic gonadotrophin (hCG) in women undergoing an IVF 30 cycle, demonstrated that implantation was detected in as many as 60% of the cycles (Simon *et al.* 1999). Of all embryos transferred in an IVF, 40% fail to implant.

There are two broad reasons for failure of implantation following replacement of apparently viable embryos. The first involves intrinsic embryonic factors that reflect retarded development or deficiencies in the health of the blastocyst itself and its ability to hatch (Gott *et al* 1990, Plachot 1992, van Kooij *et al* 1996). The

5 second relates to extrinsic factors that imply a lack of implantation receptivity in the endometrium (Edwards 1986, Yaron 1994). Moreover, successful implantation is dependent on the synchrony of embryonic development and endometrial maturation that is largely controlled by the ovarian hormone milieu.

10 Recently it has become apparent that fertility drugs used for the super-ovulation of women undergoing IVF are predominantly responsible for the compromised implantation receptivity observed on both sides of the embryonic/maternal interface. Ertzeid and Storeng demonstrated the detrimental effects of gonadotropins on implantation using a series of cross-over embryo transfer

15 experiments (Ertzeid *et al.* 2001). Embryos from super-ovulated and non-stimulated females were transferred to separate uterine horns in the same super-ovulated or non-stimulated pseudo-pregnant recipient mice. A significant decrease in implantation was observed in the uterine horns receiving embryos from super-ovulated donors and even more dramatically in both horns of super-ovulated recipients.

Highly elevated concentrations of estrogen result from ovarian stimulation in IVF. These are suspected to alter the cascade of hormonal events and subsequent expression of cytokines that the oocytes, embryos and uterine endometrium

25 would ordinarily be exposed to in an unstimulated menstrual cycle. Add to this the physiological challenge of *in vitro* culture, largely devoid of growth factors, and it is not unexpected that IVF derived embryos might be compromised at the time of implantation.

30 Despite substantial advances in the recovery and maturation of multiple oocytes from unstimulated cycles, the practice of oocyte *in vitro* maturation (IVM) is as yet clinically unaccepted. With the prospect that super-ovulation will remain the mainstay of IVF, other approaches to improving implantation rates continue to be explored.

The development of physiological based culture media constituents has gone some way to improving the development of embryos in culture for up to 6 days. This extended culture enables self-selection of the most viable embryos for 5 transfer, but as a consequence this approach has a high attrition rate of embryos. Co-culture of embryos on a mono- or bi-layer of support cells (e.g. endometrial cells) has also provided a method for improving the development of embryos in culture presumably via the stimulus of growth factors. More directly the addition of a variety of growth factors to media has been explored and shown to be of 10 benefit (Sjöblom *et al.* 2000).

Maintaining a receptive endometrium through administration of human chorionic gonadotropin or progesterone has been practiced since the early days of IVF. In fact only after additional progesterone support was given in the luteal phase of 15 the cycle, did the world's first IVF pregnancies result. It has long been recognised that the elevated estrogen profiles produced by the fertility drugs effectively advance the endometrial tissue dating by approximately one day (Noyes *et al.* 1950; Pittaway *et al.* 1983; Garcia *et al.* 1984). Compound this with the fact that embryos are routinely transferred into the uterus at the 2 – 8 cell 20 stage (48-72 hrs prematurely to what occurs naturally) and it is clear that IVF results in an asynchronous environment for implantation.

Implantation of a hatched blastocyst is described as consisting of three phases:

- a) apposition – where the embryo comes into initial physical contact with the glycoconjugate coat of the endometrial epithelium (called the glycocalyx).
- 25 b) adhesion – where the embryo undergoes cell to cell, and cell to matrix binding with molecules derived from the apical cells on the endometrium.
- c) invasion – where the embryo penetrates through the epithelial layer of 30 the endometrium by intruding between cell junctions as occurs in the human or by displacement of the cells found in some animals (e.g. mice).

Super-ovulation has been postulated to alter electronegative properties of the glycocalyx and apical cell surface of the endometrium. In this way, fertility drugs may reduce effective apposition and adhesion of a transferred embryo (Ronnberg *et al.* 1985).

5

At least two therapeutic approaches to improving implantation rates in IVF embryos have been practiced in humans. The first draws on the observation that inclusion of the glycoaminoglycan, hyaluronan, in the media containing embryos for transfer, results in a higher implantation rate than media devoid of this polysaccharide (Gardner *et al.* 1999). The concentration of hyaluronan increases in the uterus at the time of implantation in the mouse (Zorn *et al.* 1995) and is suggested to facilitate implantation by a variety of means such as increasing cell-cell and cell-matrix adhesion and indirectly through promotion of angiogenesis. Despite a lack of published trials in humans, hyaluronate is now present in a number of commercially available embryo transfer media.

10

One therapy that has undergone clinical trials and is described in US 6,196,965, is the use of a fibrin sealant. The first experiments with a fibrin sealant were carried out in 1981, and by 1988 it had been proven safe to use in humans

15

(Rodrigues *et al.* 1988).

20

US 6,196,965 is based on the technique used in a randomised clinical trial published in 1992 (Feichtinger *et al.* 1992). Embryos are transferred in a catheter, sandwiched between small quantities of thrombin/aprotinin and then fibrin. The results of the trial demonstrated no significant difference in pregnancy rate between the control and treatment group (546 patients), but a significant decrease in ectopic pregnancies in the fibrin sealant group.

25

The rationale and theoretical basis for the two therapeutic approaches described above are different. Hyaluronate is added to transfer media in the hope that it will induce a more physiologically receptive environment for implantation. There is, however, an absence of direct evidence at the molecular level proving this hypothesis. Fibrin sealant therapy on the other hand, is used to encase the embryos in an adhesive plug that will theoretically be glued onto the endometrium. Expulsion of embryos from the uterine cavity by muscular

30

contraction and avoidance of ectopic pregnancy was the predominant motivation for the fibrin sealant in the Feichtinger trial (Feichtinger *et al.* 1990), although other investigators have hypothesised that fibrin would improve the adhesion phase of implanting embryos (Rodrigues *et al.* 1988).

5

In addition to the previously described therapeutic approaches, the specification for international application no. PCT/US98/15124 (published as WO 99/05255) describes the enhancement of implantation by contacting the embryo with a lipid-modified adhesion molecule so as to modify the development of the embryo. The 10 technique of "protein painting" embryos with glycosylphosphatidylinositol (GPI) linked Qa-2 proteins to increase the cell division rate is described.

Protein painting is a method for modifying the external antigens of cell membranes without gene transfer. The method exploits the ability of GPI linked 15 proteins to spontaneously anchor to cell membrane via their lipid tails. The method described in the specification for international application no. PCT/US98/15124 (WO 99/05255) requires that a naturally occurring (or genetically altered) protein is inserted into an embryo membrane with an attached GPI lipid tail. Isolated GPI-anchored proteins are stated as having an unusual 20 capacity to reintegrate with a cell-surface membrane. The molecules that can be used for modifying an embryo in this way are therefore confined to a rather limited group.

As described herein, the inventors have now found that embryos can be modified 25 with a range of selected synthesised molecules (modified glycolipids and glycolipid-attachment molecule constructs) and have the ability to bind with mucus, and/or mucus components, and/or cell membranes. The molecules are prepared exogenously by chemical or biological processes.

30 Not only has the modification of embryos by the method of the invention been successfully demonstrated in an *in vitro* culture system, but animals have given birth to healthy offspring derived from modified embryos. Embryos prepared in accordance with the invention appear to be developmentally indistinguishable from their unmodified counterparts.

It is an object of this invention to provide a modified embryo for the enhanced implantation of the embryo into the endometrium of an animal, or to at least provide the public with a useful choice.

5

### STATEMENTS OF INVENTION

In a first aspect of the invention there is provided a glycolipid-inserted embryo for the preparation of an embryo modified for enhancing the implantation of the 10 embryo into the endometrium of an animal, where:

- the embryo has a glycolipid having lipid tails inserted into a cell membrane of the embryo or into the zona pellucida of the embryo; and
- the glycolipid has been modified to incorporate a binding part wherein said binding part is adapted to enable binding to an attachment 15 molecule.

Preferably, the glycolipid has been modified to incorporate the binding part prior to the insertion of its lipid tails into the cell membranes of the embryo or into the zona pellucida of the embryo.

20

In a second aspect of the invention there is provided an embryo modified for enhancing the implantation of the embryo into the endometrium of an animal, where:

- the embryo has an attachment molecule which is capable of attaching 25 to the endometrium; and
- the attachment molecule is linked to the embryo by a glycolipid having lipid tails inserted into a cell membrane of the embryo or into the zona pellucida of the embryo; and
- the attachment molecule and the glycolipid have each been modified to incorporate a binding part adapted to enable the attachment molecule 30 and the glycolipid to be bound together via their respective binding parts either directly or through a bridging molecule.

Preferably, the modification to the glycolipid is to the carbohydrate portion of the glycolipid.

Preferably the attachment molecule is a molecule known or adapted to interact  
5 with the endometrium, mucus, mucin, or other endogenous or exogenously provided components of mucus. More preferably the attachment molecule is a known endometrial attachment molecule.

10 In one embodiment of the invention the binding interaction between the attachment molecule and the glycolipid are bound by way of non-covalent binding interactions including ionic, van de Waals, water exclusion, electrostatic, hydrogen bonding and chelation binding or via covalent bonding.

15 In one embodiment of the invention the binding interaction between the attachment molecule and the glycolipid is avidin-biotin binding. In one preferred embodiment the binding part of the glycolipid comprises biotin and the binding part of the attachment molecule comprises avidin. In an alternative preferred embodiment the binding part of the glycolipid comprises avidin and the binding part of the attachment molecule comprises biotin.

20 In one embodiment of the invention the binding interaction between the attachment molecule and the glycolipid is through a bridging molecule. The bridging molecule may comprise avidin in the case of the binding part of both the attachment molecule and the glycolipid comprising biotin. Alternatively, in the 25 case of the binding part of both the attachment molecule and the glycolipid comprising avidin, the bridging molecule may comprise biotin.

30 In one embodiment of the invention the binding interaction between the attachment molecule and the glycolipid may be a chelation interaction. The binding parts of the attachment molecule and the glycolipid may therefore be bridged by a chelated metal ion (e.g.  $\text{Co}^{2+}$ ,  $\text{Ni}^{2+}$  or  $\text{Cu}^{2+}$ ) and a poly-histidine recombinant protein. The chelator may be attached covalently or non-covalently (e.g. via biotin or avidin) to the glycolipid.

The glycolipid may be any glycolipid capable of inserting its lipid tails into the cell membranes of the embryo or into the zona pellucida of the embryo such as phosphoglycerides or sphingolipids. The glycolipid may be a natural molecule or a modified (e.g. biotinylated) glycolipid. Preferably the modified glycolipid is a 5 biotinylated glycolipid either of the ganglioside class that contains sialic acid groups, or the neutral class that contains galactose.

The attachment molecule may be any molecule that has a binding affinity for molecules on cell membranes (e.g. receptor sites and blood group related 10 antigens) including their mucus coat. Preferably the cell membrane is endometrial. In particular, the attachment molecule is preferably a protein, a peptide (such as poly L-lysine) a carbohydrate, an acyl group, a polymer, or an immunoglobulin such as immunoglobulin G (IgG) or a lectin. Alternatively, the attachment molecule may be a synthetic molecule (e.g. polyvinyl pyrrolidine, or 15 an acyl group) which reacts with molecules expressed on cell membranes or on the mucus layer covering the cell membrane. The attachment molecule can itself be a glycolipid or glycolipid conjugate.

In a third aspect of the invention there is provided a method of preparing the 20 modified embryo of the first aspect of the invention including the step:

- contacting a glycolipid with an embryo, where the glycolipid has been modified to incorporate a binding part, wherein said binding part is adapted to enable binding to an attachment molecule either directly or through a bridging molecule, so that the lipid tails of the glycolipid insert 25 into a cell membrane of the embryo or into the zona pellucida of the embryo.

In a fourth aspect of the invention there is provided a method of preparing the modified embryo of the second aspect of the invention including the steps:

- contacting an attachment molecule with a glycolipid, where the attachment molecule and the glycolipid have each been modified to incorporate a binding part adapted to enable the attachment molecule and the glycolipid to bind together via their respective binding parts either 30

directly or through a bridging molecule to provide a glycolipid-attachment molecule construct; and then

- contacting the attachment molecule bound to the glycolipid (glycolipid-attachment molecule construct) with an embryo so that the lipid tails of the glycolipid insert into the cell membranes of the embryo or into the zona pellucida of the embryo:

5 Or including the steps:

- contacting a glycolipid with an embryo, where the glycolipid has been modified to incorporate a binding part adapted to enable binding to an attachment molecule either directly or through a bridging molecule, so that the lipid tails of the glycolipid insert into a cell membrane of the embryo or into the zona pellucida of the embryo; and then
- contacting the glycolipid-inserted-embryo with an attachment molecule, modified to incorporate a binding part wherein said binding part is adapted to enable binding to the binding part of the glycolipid either directly or through a bridging molecule.

10 Preferably the glycolipid has been modified to incorporate a binding part comprising biotin and the attachment molecule has been modified to incorporate a binding part comprising avidin.

15 Alternatively, the glycolipid has been modified to incorporate a binding part comprising avidin and the attachment molecule has been modified to incorporate a binding part comprising biotin.

20 In the case of binding of the glycolipid to the attachment molecule through a bridging molecule, it is preferred that the bridging molecule comprises avidin and that both the glycolipid and the attachment molecule have been modified to incorporate binding parts comprising biotin.

25 In a fifth aspect of the invention there is provided a method of enhancing the implantation of an embryo into the endometrium of an animal, preferably a human, or domesticated animal, comprising the steps:

- preparing a modified embryo according to the second aspect of this invention, and
- transferring the modified embryo to the uterus of the animal.

5 In one embodiment of the invention the modified embryo is prepared from a species, hybrid or variety of animal that is the same as the species, hybrid or variety of animal, to the uterus of which it is transferred. In an alternative embodiment, the species, hybrid or variety differ.

10 In a sixth aspect of the invention there is provided a glycolipid-attachment molecule construct for use in enhancing the implantation of an embryo into the endometrium of an animal comprising a glycolipid modified to incorporate a binding part and an attachment molecule modified to incorporate a binding part wherein the respective binding parts are adapted to enable the modified 15 glycolipid and the modified attachment molecule to bind each other either directly or indirectly through a bridging molecule.

In a seventh aspect of the invention there is provided a method of enhancing the implantation of an embryo into the endometrium of an animal including the steps 20 of:

- introducing a construct of the sixth aspect of the invention into the uterus of the animal so that the construct becomes localised to the endometrium; and then
- transferring the embryo to the uterus of the animal.

25 In an eighth aspect the invention provides a kit for use in enhancing the implantation of an embryo of an animal comprising one or more preparations of a glycolipid-attachment molecule construct of the sixth aspect of the invention.

30 While the invention is broadly defined as above, those persons skilled in the art will appreciate that it is not limited thereto and that it also includes embodiments of which the following description provides examples. In addition, the present invention will be better understood from reference to the figures of the accompanying drawings.

**FIGURES**

5      Figure 1 - Schematic legend

Figure 2 - Schematic representation of natural glycolipid insertion. A naturally occurring glycolipid (e.g. glycolipid A or Le<sup>b</sup>) is inserted into a cell membrane (e.g. RBC, embryonic cell or endometrial cell).

10

Figure 3 - Schematic representation of biotinylated glycolipid insertion. A biotinylated glycolipid (BioG) is inserted into a cell membrane (e.g. RBC, embryonic, endometrial cell).

15

Figure 4a - Schematic representation of terminal an attachment molecule (synthetic carbohydrate) and a glycolipid bound together. A biotinylated glycolipid (e.g. BioG) is inserted into a cell membrane, conjugated to an avidin molecule and a biotinylated synthesised blood group A antigen (e.g. Atri-PAA) is attached.

20

Figure 4b - Schematic representation of an attachment molecule (IgG) and a glycolipid bound together. A biotinylated glycolipid (e.g. BioG) is inserted into a cell membrane, conjugated to an avidin molecule and a biotinylated IgG is attached.

25

Figure 4c - Schematic representation of an attachment molecule (lectin) and a glycolipid bound together. A biotinylated glycolipid (e.g. BioG) is inserted into a cell membrane, conjugated to an avidin molecule and a biotinylated lectin is attached.

30

Figure 5 - Schematic representation of the interaction between a modified embryo and a cell type. A BioG transformed cell of an embryo is conjugated to avidin and a biotinylated specific antibody (e.g. BiolgG<sup>A,B</sup>). The resulting antibody transformed cell is then exposed to another cell type (RBC, embryo) expressing

the corresponding antigen (e.g. blood group A or B) resulting in adhesion between the two cell types.

5 Figure 6 - Schematic representation of the interaction between a modified embryo and a cell type. A BioG transformed cell of an embryo is conjugated to avidin and a biotinylated lectin (e.g. Bio-UE) is attached. The resulting lectin transformed cell is then exposed to another cell type (e.g. endometrial) expressing the corresponding antigen resulting in adhesion between the two cell types.

10

Figure 7 - Schematic representation of BioG/Av/BioIgG insertion into embryos. Adhesion is determined by reaction with antibody sensitised cells (IgG bearing) via anti-human Ig.

15 Figure 8a - Schematic representation of one mechanism for demonstrating the adhesive protein model using BioIgG<sup>A,B</sup> or BioG/Av transformed mRBCs (murine red cells), and mouse embryos. Mouse embryos (right) will attach to the BioIgG<sup>A,B</sup> transformed cells (eg RBCs) (left).

20 Figure 8b - Schematic representation of one mechanism for demonstrating the adhesive protein model using BioIgG<sup>A,B</sup> or BioG/Av transformed mRBCs, and mouse embryos. Mouse embryos (right) that have been exposed to BioIgG<sup>A,B</sup> (sensitised) will attach to the Bio/Av transformed cells (left).

25 Figure 9a - Schematic representation of BioUE adhesion model showing direct interaction between a BioUE transformed embryo (left) and H antigen bearing endometrial cells or red cells (right)

30 Figure 9b - Schematic representation of BioUE transformed embryos (left) reacting with group O secretor mucus as determined by inhibition of reactivity of BioUE transformed embryos with group O red cells (human red cells - hRBC).

**DETAILED DESCRIPTION**

The following description of this invention relates primarily to the use of biotin/avidin binding. It is important to note that other combinations of attachment 5 molecule and glycolipid modified to incorporate a binding part which allow high affinity conjugation (i.e. covalent or non-covalent bonding) between the attachment molecule and glycolipid are suitable.

Terms or expressions used to describe this invention are defined as follows:

10

- i. endometrium - The tissue lining the internal surface of the uterus. It is this layer of epithelial cells and extracellular matrix (i.e. mucus) that the implanting embryo comes into first contact with. The epithelial and underlying stromal cell layer cyclically thickens, secretes mucus 15 and is shed from the body under the hormonal influence of the menstrual cycle.

20

Attachment to the endometrium lining may be by interaction between the attachment molecule and one or more components of the endometrium, including membranes of the epithelial cells, mucus, mucin components of the mucus, or an exogenously introduced component of the mucus.

25

30

- ii. zona pellucida - The glycoprotein coat that surrounds the mammalian oocyte (egg) and embryo from the 1-cell to blastocyst (6 day old) stage of development. Prior to embryo attachment and implantation, the zona pellucida is shed from the embryo by a number of mechanisms including proteolytic degradation. The zona pellucida functions initially to prevent entry into the oocyte by more than one sperm, then later to prevent premature adhesion of the embryo before its arrival into the uterus.

iii. attachment molecule - Any carbohydrate or oligosaccharide, glycolipid, glycoconjugate, protein or synthetic molecule that can interact with one or more components of the targeted tissue (e.g. endometrium) to localise the attachment molecule to the tissue.

5 Desirably the attachment molecule will interact with endometrium and not the embryo.

The attachment molecule may be selected from natural or synthetic carbohydrates or oligosaccharides, glycolipids, glycoconjugates 10 proteins, peptides, antibodies, lectins, polymers such as polyvinyl pyrrolidine, and functionally equivalent derivatives thereof.

iv. glycolipid - Any lipid-containing carbohydrate, including phosphoglycerides (e.g. glycosylinositolphosphatidylinositol) and sphingolipids (e.g. glycosyl ceramides, cerebroside sulphate, and 15 gangliosides).

v. binding part - The portion of the attachment molecule or of the glycolipid that interacts (or docks) with the attachment molecule or glycolipid respectively, or with a bridging molecule, to provide a non- 20 covalent or covalent bond between the binding part and the attachment molecule, glycolipid, or bridging molecule, thereby providing a glycolipid-attachment molecule construct.

25 vi. bridging molecule - a molecule that links the binding part of the glycolipid with the binding part of the attachment molecule. For example, avidin (interacting with biotin on either the glycolipid or the attachment molecule), or a chelator (interacting with a poly-histidine).

30 vii. biotin - Biotin is a water-soluble vitamin (H). It consists of fused imidazolinone and thiophan rings with a pentanoate side-chain attached to the latter. Biotin has an extremely high affinity to bind the protein avidin via its imidazolidine ring. The use of the term "biotin" in

the description is intended to be understood to include derivatives of biotin with functional equivalence.

5           viii. avidin (Av) - Avidin derived from chicken egg white is a glycoprotein with a molecular mass of 67 kDa. It contains four identical sub-units, each bearing a biotin-binding site. The use of the term "avidin" in the description is intended to be understood to include derivatives of avidin with functional equivalence.

10           ix. Chelation - Chelation is defined as the strong binding that occurs between chelated metal ions and proteins. Certain chemical groups called ligands, such as iminodiacetate and nitrilotriacetate, form a stable metal coordination complex (or metal chelate) with a divalent transition metal ion eg  $\text{Ni}^{2+}$ ,  $\text{Co}^{2+}$  or  $\text{Cu}^{2+}$ . Peptides containing poly-15 histidine residues strongly bind to such a metal chelate by participation of imidazole side-chains in chelation.

20           x. BioG (Biotinylated glycolipid) - Biotin coupled to a glycolipid.

25           xi. BiolgG (Biotinylated Immunoglobulin G) - Biotin coupled to immunoglobulin G. When the antibody has specificity this is indicated as a superscript. For example BiolgG<sup>D</sup>, BiolgG<sup>ALeb</sup>, BiolgG<sup>A,B</sup> and BiolgG<sup>Leb</sup> are biotinylated antibodies directed against the D, ALe<sup>b</sup>, AB and Le<sup>b</sup> antigens respectively.

xii. Lectin - is a sugar-binding protein of non-immune origin that agglutinates cells or reacts with glycoconjugates.

30           Glycolipids can insert into cell membranes without damaging cells. The invention provides for the insertion of synthetic molecules (including exogenously prepared glycolipid-attachment molecule constructs) into the glycoprotein coat of early embryos (zona pellucida) and the lipid bi-layer membrane of embryo cells that are involved in embryo implantation.

While this technology is applicable to embryo implantation in a wide variety of animals, it is most relevant to humans. However, this invention is not limited to human embryo modification and implantation. In particular inter species transfer, embryo modification and implantation is contemplated.

5

One or several intercellular interactions can be targeted for improvement using the technology of this invention. This may be a direct adhesion mechanism, or other mitotic stimulus or cell recognition events. While the attachment molecule and glycolipid may be derived from natural or synthetic sources, the assembly of 10 the attachment molecule and the glycolipid is synthetic i.e. performed at least in part exogenously. The covalent or non-covalent, direct or indirect, attachment of the attachment molecule to the glycolipid may occur either before or after the insertion of the glycolipid into the cell membrane .

15 One combination that employs biotin/avidin binding is a biotinylated glycolipid as the primary insertion molecule, an avidin bridging molecule, and a biotinylated attachment molecule (in this case an antibody or lectin or carbohydrate). The insertion process operates by exploiting the high binding affinity of avidin for biotinylated molecules, essentially forming a sandwich complex. Firstly, the 20 biotinylated glycolipid is inserted into the cell membrane to provide an anchor for the application of subsequent molecules. Secondly, the inserted cell membrane is treated with avidin that binds to the biotinylated glycolipid. The final phase involves conjugation of the inserted molecules with the biotinylated endometrial adhesion molecule. To demonstrate this invention, the attachment molecules are 25 the immunoglobulin G antibody, a lectin (*Ulex europeaus*) and glycolipid. However, it must be emphasised that these molecules could be substituted by any one of a variety of natural or synthetic molecules.

30 Immunoglobulin G and lectin were chosen for development of the invention because of the ease in which molecular insertion and cell adhesion between two cell types can be confirmed using serological techniques. Preliminary development and proof of principle for each phase of the invention was carried out using human RBCs. Essentially the red cell membrane is a fluid membrane not too dissimilar to the embryo membrane, but much easier to obtain and

handle. Thereafter, the insertion technique was tested on mouse embryos ranging from the 2-cell to blastocyst stage of development.

At each developmental phase, it was important to investigate the potential risk of  
5 detrimental effects of the invention on embryonic development and maternal health. Initially, the morphological development of treated embryos was compared with control embryos cultured in vitro. The outcome of normal live births from transferred treated embryos into recipient mice provides evidence of the safety of the invention. Finally, the ongoing reproductive performance of the  
10 treated offspring proves that no lasting detrimental effects are present.

There are several steps in the practice and demonstration of the utility of this invention;

- Inserting natural glycolipids which may be potential adhesion/communication molecules into embryo membranes (in particular thorough carbohydrate-carbohydrate interactions, or through carbohydrate-protein interactions);
- Inserting modified (biotinylated) glycolipids in embryo membranes as a mechanism to attach biotinylated molecules through an avidin bridge;
- Attaching IgG membrane/mucus adhesion molecules to embryo membranes;
- Attaching lectin membrane/mucus adhesion molecules to embryo membranes;
- Proving the embryo is unharmed by the processes above.

25 Adhesion of embryo's to cell membranes was proven initially by reactivity against red cells and secondarily against endometrial cells. For all intents and purposes red cells are equivalent to endometrial cells as they are of a similar size and are both fluid membranes. In some instances red cells were considered as being  
30 "surrogate" endometrial cells. A serological technique known as rosetting (Indiveri *et al* 1979), was used to demonstrate the adhesive capacity of the embryo's which had been modified with adhesive proteins (eg antibodies or lectins) with other cells. This was either done directly where the attached binding protein reacted with the corresponding antigen on the red/endometrial cells or through a

bridge such as anti-IgG. In this way it was possible to prove that not only had the adhesion molecule been successfully inserted into the embryo, but that an artificial adhesion between two cell types had been created. For the purposes of demonstration the specificity of the antibodies selected were those chosen to 5 react with red cells, or for which glycolipid antigens existed which could be inserted into cells to make them express the desired antigen. In the actual application of this technology red cell specific antibodies/lectins would be replaced with antibodies that detect antigens on the endometrial cells and/or mucins. The specificity of the antibodies or lectins which can be used is limited 10 only by availability.

In order to insert molecules into cell membranes biotinylated glycolipids (BioG; Example 1) and biotinylated antibodies (BiolgG; example 2) had to be prepared (when they could not be purchased). The insertion phenomenon using BioG and 15 avidin concentrations were optimised using red cells (example 3).

#### **Insertion Media**

Stock glycolipids for insertion were prepared in a solvent free saline (see Example 4) to ensure protection from the reported detrimental effects of alcohols 20 in sensitive embryonic cells (Lau *et al.* 1991). The stock solution containing saline suspended (micelles) of glycolipids was diluted in various cell culture media or saline for insertion experiments. The results in Example 5, are in agreement with other investigators that the presence of serum, plasma or detergents is unnecessary for insertion to occur (Zhang *et al.* 1992). In contrast 25 with previous reports, the presence of albumin in the M2 media in Example 5, does not impede the insertion process. Therefore, the insertion solution is effective in culture media with and without the presence of protein. Examples 6, 7 and 8 clearly demonstrate successful insertion of glycolipids into endometrial cells and embryo's.

**Inserting natural glycolipids which may be potential adhesion/communication molecules into embryo membranes** (in particular through carbohydrate-carbohydrate interactions, or through carbohydrate-protein interactions).

5

It is well established that cells can communicate through the low avidity binding characteristics of carbohydrate-carbohydrate interaction. These low affinity reactions are believed to be involved in cellular communication and adhesion (Bovin, 1996; Hakomori 1996; Mikhalehik *et al* 2000; Wang *et al* 2001). Natural glycolipids can be added to the surfaces of embryo and endometrial membranes, thus modifying their carbohydrate expression (examples 6 and 7). Such modified cells may then potentially be available to react either with reactive carbohydrates expressed on the endometrial lining (membrane or mucus) or may react with carbohydrate reactive proteins expressed on the endometrial surfaces.

15

**Inserting modified (biotinylated) glycolipids in embryo membranes as a mechanism to attach biotinylated molecules through an avidin bridge**

Like the natural glycolipids (examples 6 and 7) biotinylated glycolipids are able to be inserted into the embryo membranes including the zona pellucida (example 8).

20

The biotinylated ganglioside once inserted into the membrane is able to be reacted with avidin, which can then pick up biotinylated molecules, thus modifying the surface of the embryo (examples 9 – 14).

**25 Attaching IgG membrane/mucus adhesion molecules to embryos membranes**

Several mechanisms were examined to show the attachment of IgG adhesion molecules to cell membranes. These included direct attachment of an antibody which could react with the membrane of another cell for example red cells (examples 9 and 10) and endometrial cells (example 12). Example 9 demonstrates the direct rosetting method, with an antibody specific to the red cell protein antigen D. Alternatively a multistage adhesion can be induced where some components are added to the embryo and others to the cell for adhesion. This can be seen in Example 10, where the carbohydrate specific IgG attachment

molecule BioIgG<sup>A,B</sup>, was inserted into RBCs which adhered to embryos expressing the reactive antigens. An alternative interaction was also demonstrated, where embryos were coated with BioIgG<sup>A,B</sup>, and were shown to complex with RBCs inserted with BioG-avidin.

5

Additionally a bridging molecule such as anti-IgG could also be used to bridge IgG attached to both the membranes of the embryo and another cell, in this case red cells (example 11) which it is desired the embryo attaches to. In this example, (example 11), human anti-D sensitised RBCs were used to demonstrate the adhesive properties of embryos inserted with BioIgG, an immunoglobulin G with no specificity to any known antigen. Addition of anti-IgG to the BioIgG embryos and anti-D sensitised RBCs caused indirect rosetting between the two cell types. Ideally an antigen, which is expressed on endometrial cells but is absent on the embryo, would be an appropriate antibody target. In the absence of easy availability of such a reagent and also to demonstrate a further potential application, we inserted antigens into the endometrial cell membrane for which a biotinylated antibody was available. These inserted antigens become integral parts of the cell membrane and as such can be considered part of the membrane (example 6). Blood group antigens Le<sup>b</sup> and ALe<sup>b</sup> were added to endometrial cells and the corresponding biotinylated antibodies were attached to embryo's via BioG-avidin (example 12). The attachment of the endometrial cells to the embryo's proves the mechanism of modified embryo induced adhesion. Additionally this process opens up the opportunity to both insert molecules into the embryo and the recipient (e.g. lavage) to induce/enhance adhesion between the embryo and the recipient.

These various examples illustrate the use of IgG that can target either carbohydrate or protein antigens as attachment molecules for various cell membrane attachment interactions.

30

#### **Attaching lectin membrane/mucus adhesion molecules to embryos membranes**

Lectins are non-immunological carbohydrate binding proteins. In example 13, the biotinylated lectin *Ulex europaeus* (BioUE) was inserted into embryos to

demonstrate a direct adhesive interaction with group O RBCs bearing the H type 2 carbohydrate antigen (specific antigen for UE). Additional the same phenomenon can be demonstrated with binding to endometrial cell culture (example 14)

5

Because the mucins will cover endometrial cells in utero the ability to modify the embryo to react with antigens on mucus was also demonstrated. Lectins were used for this purpose but antibodies reactive with mucus would be equally as applicable. In example 13 *Ulex europaeus* modified embryos were reacted with H type 2 containing mucus (obtained from human group O salivary secretions). In an inhibition assay the addition of H type 2 bearing mucus inhibited red cell rosette formation, illustrating that mucus had bound to the UE inserted embryos thus preventing the lectin reacting with red cells.

15 **15 Proving the embryo is unharmed by the processes above.**

An essential requirement of any implantation therapy is that it must not induce any detrimental effects on the normal fetal growth of the treated embryo, or the off spring, or the mother. Preliminary experiments with BioG inserted embryos showed no difference in morphology or zona hatching rate from control embryos 20 during 5 days of *in vitro* culture (Example 15). Similarly, no difference from control embryos was noted (although not subjected to statistical analysis) between the pregnancy, live birth rate and normalcy of offspring in treated embryos (BioG, BioG/Av/BiolgG, ZI and ZF) when transferred into recipient mice (Example 16 and Example 17). Ultimately, the ongoing fertility rate and second 25 generation pups of the offspring resulting from treated embryos was apparently normal (Example 18).

**EXAMPLES****Example 1**

5 Biotinylated gangliosides (BioG) were prepared using a modified procedure described by Wilchek and Bayer (1987). The extraction and purification of porcine gangliosides is carried out using established techniques (Karlsson 1987, Ladisch *et al.* 1987, Ledeen *et al.* 1982).

- 10 1. Dried gangliosides purified from porcine brains, were reconstituted in PBS with the aid of sonification.
2. The ganglioside sialic residues were oxidized by the addition of sodium m-periodate.
3. The solution was subjected to 24 hr dialysis to remove the resulting peroxide.
- 15 4. The oxidised ganglioside was incubated with biotin amidocaproyl hydrazide (Sigma B-3770) for 1hr.
5. The solution was subjected to further overnight dialysis in water to remove excess biotin amidocaproyl hydrazide.
- 20 6. The resulting solution was dried via rota evaporation and reconstituted in 50% methanol water. Further evaporation was performed under nitrogen gas in a reduced pressure desiccator overnight.

**Example 2**

25 Biotinylated immunoglobulin G was prepared using a method described by O'Shannessy 1990). Using similar procedures to those outlined in Example 1, the IgG was oxidised with a periodate solution and incubated with biotin amidocaproyl hydrazide.

**Example 3**

30 Optimum BioG insertion concentrations and conditions were established by labelling the inserted BioG RBCs with avidin-FITC. The results are outlined in Table 1.

**Table 1. Fluorescent signal of human RBCs inserted with a range of BioG and labelled with avidin-FITC concentrations.**

	BioG mg/ml			
	10	5	2.5	0
Avidin-FITC mg/ml				
0.90	++++	++++	+++	-
0.45	++++	++++	+++	-
0.33	++++	++++	+++	-
0.16	++++	++++	+++	-
0	-	-	-	-

The optimum insertion concentration of BioG was 5 mg/ml. The minimum concentration of avidin required for adequate detection of BioG at 5 mg/ml concentration, was 0.16 mg/ml. The optimum minimum insertion time was determined to be 1 hour as seen in Table 2.

**Table 2. Fluorescent signal of human RBCs incubated with BioG for a variety of times, then labelled with avidin-FITC.**

	Hours of incubation								
	0.25	0.5	0.75	1	1.5	2	4	6	26
	+++	+++	+++	++++	++++	++++	++++	++++	++++

The amount of fluorescent signal score for the 2hr incubation tube reduced from 10 4+ to 3+ after avidin labelling 5 days post insertion, suggesting minimal loss of inserted molecules over time.

#### **Example 4**

Stock glycolipids for insertion were prepared in solvent free saline to protect 15 sensitive cells such as embryos from solvent exposure during insertion treatment.

1. Purified dried glycolipids (e.g. Le<sup>b</sup>, A, or biotinylated ganglioside) were dissolved in a glass tube with 50% methanol/water to give a 10 mg/ml solution.
- 20 2. The solution was filtered with a 0.22 micron solvent resistant filter into a sterile glass tube.

3. A 150  $\mu$ l aliquot of the solution was marked on the side of the glass tube to indicate the end point of evaporation. A further 850  $\mu$ l aliquot was placed in the glass tube to give a total of 1 ml (containing 10 mg).
4. The tube was placed under a gentle stream of nitrogen gas in a dry heat 5 block at 50°C until the meniscus was reduced to the marked evaporation line.
5. The solution was made up to 200  $\mu$ l with a balanced salt solution of sterile PBS by adding 20  $\mu$ l of 10x phosphate buffered saline (PBS) and 30  $\mu$ l of 18 m $\Omega$  water.
10. The final 50 mg/ml solution was aliquoted into sterile microcentrifuge tubes and frozen at -70°C or freeze dried (to be later reconstituted with water).
15. Samples from the stock solution were then taken for dilution in cell culture media for transformation experiments.

15

**Example 5**

The requirement for plasma or serum in the insertion media was shown not to be necessary. The ability for fluorescein isothiocyanate-labelled avidin- (avidin-FITC Sigma A-2901) to bind to biotin formed the basis of detecting inserted BioG in 20 RBCs when viewed under microscope fluorescence at 470 nm. In this study, a comparison in the degree of fluorescent signal in avidin-FITC treated BioG human RBCs was carried out for insertion solutions in a variety of tissue culture or serology media.

25. 1. 5 $\mu$ l of packed RBCs were mixed with 30 $\mu$ l of 2mg/ml BioG (final conc. 12 $\mu$ g/ml of packed RBCs) in one of the following aqueous media for 2hrs at 37°C with frequent mixing. The range of aqueous media included: Celpresol (CSL Biosciences, Australia), M2 media mouse embryo handling media (Sigma M5910), SQC mouse culture media (Vitrolife, Sweden), Medicult human embryo culture media (Medicult Denmark) and 30 PBS (made in-house).

2. The RBCs were washed 3x in saline by centrifugation and incubated with 9.5 $\mu$ l of avidin-FITC for 1hr at 37°C
3. The cells were washed 3x in saline and viewed under a fluorescent microscope at 470nm.

5

The concentrations and fluorescent microscopy results are outlined in Table 3.

**Table 3. Fluorescent signal of human RBCs inserted with BioG and labelled with Avidin-FITC**

10

Insertion media	Celpresol albumin - free	PBS albumin - free	SQC albumin -free	M2 albumin 10%	plasma
Experimental	+++	++	+++	++++	++
Negative Controls	-	-	-	-	-

The presence of a clear fluorescent signal in both M2 and SQC cell culture media deemed them to appropriate for routine embryo insertion experiments.

15 **Example 6**

The ability of natural glycolipids to insert into cell membranes was tested by inserting glycolipid A into endometrial cells. Insertion was confirmed by labelling with anti-A then by secondarily labelling with anti-mouse immunoglobulin conjugated to fluorescein isothiocyanate (anti-mouse Ig-FITC) and detected by fluorescent microscopy.

20

A 5 million/ml heterogeneous solution of murine endometrial cells was prepared by dissecting the uterine horn, scraping out the endometrial tissue, and incubating the tissue at 37°C for 1.5 hrs in 500  $\mu$ l of 0.25% pronase and 1 ml of 0.5% collagenase. After incubation the cells were washed and suspended in DMEM-F12 culture media

25

Glycolipid A was inserted and detected in endometrial cells using the following method:

30

1. Freeze dried glycolipid A was resuspended in DMEM- F12 to give a 10 mg/ml and a 1mg/ml solution.
2. Three micro-centrifuge tubes were prepared each containing a 50  $\mu$ l solution of 5M/ml endometrial cells. The following reagents were added to each micro-centrifuge tube a) 50  $\mu$ l glycolipid A (10mg/ml), b) 50  $\mu$ l glycolipid A (1mg/ml) and c) 50  $\mu$ l CMF(calcium magnesium free)-HBSS. The cells were incubated overnight at room temperature.
3. After each treatment step the endometrial cells were washed 3 times by resuspending in M2 media and centrifuging at 2000 rpm for 3 minutes. The washed cells were then resuspended in 50  $\mu$ l of M2 media.
4. Endometrial cells were subsequently reacted with anti-A by adding 50  $\mu$ l of anti-A murine monoclonal antibody to each micro-centrifuge tube and incubating at room temperature for 30 minutes.
5. To test the presence by fluorescence 10  $\mu$ l of mouse anti-Ig FITC was added to each micro-centrifuge tube containing the washed cells and incubated in dark conditions at room temperature for 30 minutes.
6. Endometrial cells were mounted on glass slides and viewed under a fluorescence microscope using a 470nm filter and photographed at 200-400x magnification.
7. The results of the experiment is outlined in Table 4

25 **Table 4. Fluorescent signal of murine endometrial cells inserted with blood group A glycolipids.**

Insertion glycolipid	Fluorescence
Glycolipid A 10mg/ml	++++
Glycolipid A 1mg/ml	+++
Negative Control	-

**Example 7**

The ability of natural glycolipids to insert into cell membranes was tested by inserting natural glycolipids A and Le<sup>b</sup> separately in murine embryos.

5      Glycolipid A and Le<sup>b</sup> were inserted into the cell membranes of zona pellucida free (ZF) murine embryos from blastocyst to hatched blastocyst stage. The insertion was confirmed by labelling with anti-A or anti-Le<sup>b</sup> respectively, then by secondarily labelling with anti-mouse immunoglobulin conjugated to fluorescein isothiocyanate (anti-mouse Ig-FITC) and detected under fluorescent  
10     microscopy.

Embryo insertion was performed in both M2 (Sigma M5910) and SQC (Vitrolife, Sweden) media using the following method:

15     1. Super-ovulated mouse embryos on day 3.5 post coitus were obtained as described in Example 16.

2. Embryos from each mouse were stored in sterile microcentrifuge tubes with M2 media.

3. Culture dishes were prepared with 3 x 50 µl micro-drops of media overlaid with mineral oil.

20     4. Embryos with zonas intact (ZI) were placed in 0.25% pronase (Sigma P8811) in CMF-HBSS media for 6 minutes at 37 °C until the zona had disappeared. All embryos were zona free (ZF).

5. All embryos were washed 3 times in M2 media after each treatment step  
25     by placing them into a fresh 100 µl drop of media using a pulled glass capillary tube and syringe.

6. The following reagents were added to separate SQC micro-drops: a) 50 µl Glycolipid A (10 mg/ml), b) 50 µl Glycolipid Le<sup>b</sup> (5mg/ml) and c) 50 µl M2 media. Equal numbers of ZF embryos were placed in the micro-drops in a  
30     5% CO<sub>2</sub>, 37 °C incubator for 120 minutes.

7. Embryos were subsequently cultured in a corresponding binding antibody for each glycolipid. The following reagents were added to separate micro-drops: a) 40  $\mu$ l anti-A murine monoclonal, b) 40  $\mu$ l anti-Le<sup>b</sup> murine monoclonal and c) 40  $\mu$ l anti-A murine monoclonal. The embryos from each group were placed in the SQC micro-drops and returned to the 5% CO<sub>2</sub>, 37 °C incubator for 30 minutes.

5

8. Embryos were transferred to a SQC micro-drop containing 20  $\mu$ l anti-mouse Ig-FITC and cultured in the drop for 1 hr in dark culture conditions (in 5% CO<sub>2</sub>, 37°C).

10 9. Embryos were mounted on a glass microscope slide in a 2  $\mu$ l drop of media and overlaid with 2  $\mu$ l of mineral oil.

10. The slides were viewed under a fluorescent microscope using a 470 nm filter and photographed at 20-40x magnification.

15 The results of each experiments performed are outlined in Table 5.

20

**Table 5. Fluorescent signal of murine embryo's inserted with glycolipids A and Le<sup>b</sup> and labelled with anti-A or anti-Le<sup>b</sup> respectively, then secondarily labelled with anti-murine Ig FITC**

Insertion glycolipid	Le <sup>b</sup> glycolipid inserted	A glycolipid inserted
Experimental	++	++++
Negative	-	-
Controls		

#### Example 8

Insertion of biotinylated gangliosides (BioG) into the cell membranes of both zona pellucida intact (ZI) and zona pellucida free (ZF) murine embryos from 2-cell stage through to hatched blastocyst stage was confirmed by a positive signal of avidin conjugated to fluorescein isothiocyanate (avidin-FITC) detected under fluorescent microscopy. Some ZI embryos underwent zona removal post BioG insertion and pre avidin-FITC treatment to clearly visualise the degree of BioG

25

insertion in the cell membrane. Embryo insertion was performed in both M2 (Sigma M5910) and SQC (Vitrolife, Sweden) media using the following method:

- 5 1. Collection of super-ovulated mouse embryos on day 1.5 to day 3.5 post coitus was performed as described in Example 16.
- 10 2. Embryos from each mouse were split equally between control and experimental groups where possible and transported from the animal facility to laboratory in separate sterile microcentrifuge tubes with M2 media.
- 15 3. A culture dish was prepared with 50  $\mu$ l micro-drops of media overlaid with mineral oil and the following reagents in separate drops: a) 5  $\mu$ l of BioG (50 mg/ml stock), and b) 5  $\mu$ l of avidin-FITC (1 mg/ml).
- 20 4. Embryos destined for ZF insertion treatment were placed in 0.5% pronase (Sigma P8811) in M2 media for 6 minutes at 37 °C until the zona had disappeared.
- 25 5. All embryos were washed 3 times in M2 media after each treatment step by placing them into a fresh 100  $\mu$ l drop of media using a pulled glass capillary tube and syringe.
- 30 6. ZF and ZI embryos were placed in the BioG micro-drop for 1-2 hours under appropriate culture conditions.
7. A group of ZI embryos were treated with 0.5% protease prior to further treatment.
8. Embryos were subsequently cultured in the avidin-FITC drop for 1 hr in dark culture conditions.
9. Embryos were mounted on a glass microscope slide in a 2  $\mu$ l drop of Citiflour (R1321, Agar Scientific, NZ) and overlaid with 2  $\mu$ l of mineral oil, to replace the need for a cover-slip. A felt tip marker was used to circle the location of the specimen.
10. The slides were viewed under a fluorescent microscope at 250-500x magnification using a 470 nm filter.

The results are outlined in Table 6.

5 **Table 6. Fluorescent signal emitted from embryos inserted with BioG and conjugated with avidin-FITC.** The data represents the results of six experiments carried out on embryos at different developmental stages from 2-cell to hatched blastocysts. Zona free (ZF) embryos were treated with pronase, while hatched blastocysts had autonomously lost the zona. Some embryos were treated with avidin-FITC after further culture post BioG insertion. Unhatched blastocysts and 10 zona intact (ZI) embryos were BioG treated with the zona retained

Expt	Embryonic stage	Outline	Result – fluorescent signal
I	2-Cell embryos freshly retrieved	a) ZI M2 media controls b) ZI M2 media experimental c) ZI SQC media controls d) ZI SQC media experimental	a) nil b) cells +++ (zona +++) c) nil d) cells +++ (zona +++)
II	4-Cell cultured from 2-Cell	a) ZF controls b) ZF experimental c) ZI controls d) ZI experimental	a) nil b) +++ c) nil d) +++
III	late morula cultured from 2-Cell	a) ZF control embryos b) BioG then pronase c) pronase then BioG	a) faint homogenous signal b) ++ to +++ c) +++ to +++++ Clear signal for polar body regardless of treatment
IV	unhatched and hatched blastocyst cultured from 2-Cell	a) hatched controls b) hatched experimental c) unhatched controls d) unhatched experimental e) arrested embryos all treated with BioG then avidin-FITC 24hrs later	a) nil (except in atretic cells) b) ++ (stronger in atretic cells) c) nil except for atretic cells d) cells +++ (zona +++) e) cells +++ (zona nil) no difference in morphology between control and experimental 24hrs post BioG
V	blastocyst to hatched blastocyst cultured from 2-Cell	a) ZI BioG and avidin-FITC day-6 b) ZI BioG day-2 with further culture then avidin-FITC day-6	a) + cells (zona ++ to +++) b) + cells (zona ++ to +++)
VI	unhatched blastocysts	BioG treatment 24 hours previous as unhatched blastocysts then avidin-FITC treated as hatching blast.s a) pronase then avidin-FITC b) avidin-FITC then pronase c) avidin-FITC no pronase	a) cells +++ to +++++ b) cells +++ to +++++ c) cells + (zona +++ to +++)

**Example 9.**

Direct adhesion between an embryo and RBCs was demonstrated using the biotinylated IgG specific for the protein antigen D (BioIgG<sup>D</sup>). In this example, D+ve human RBCs were shown to positively rosette to mouse zona free embryos

5 inserted with BioG/Av/BioIgG<sup>D</sup>. No rosetting occurred on the surface of untreated mouse embryos nor those inserted with BioG/Av only.

Mouse zona free embryos were inserted with BioG/Av and BioIgG<sup>D</sup> using the following method:

10 1. Zona free day 3.5 mouse embryos were incubated at 37°C for 1.5 hours in a 50µl microdrop containing 5µl of BioG (50mg/ml), then washed 3x in M2 media.

15 2. The embryos underwent a 2<sup>nd</sup> conjugation step where they were exposed to 5 µl of avidin (1 mg/ml) in a 50 µl micro-drop of media for 60 minutes at 37 °C, and washed.

3. Finally, the embryos were incubated in a 50µl microdrop containing 25µl of BioIgG<sup>D</sup> (titre 1:1000) for 1 hour at 37°C.

4. The embryos were washed 3x in M2 media and placed in a fresh well of M2 media ready for rosetting with D +ve human RBCs.

20 The results are outlined in Table 7.

25 Table 7. BioIgG<sup>D</sup> transformed mouse embryo rosette experiment. D +ve human RBCs adhere to mouse embryos that are transformed with BioIgG<sup>D</sup> (Exp. group 3). This demonstrates the ability for antibody transformed embryos to adhere to a protein antigen on surrogate endometrial cells. No RBC adhesion was observed in either negative control groups.

	Experimental group		
	1	2	3
Embryo configuration	untreated	BioG/Av	BioG/Av/BioIgG <sup>D</sup>
RBC type	D+ve	D+ve	D+ve
Rosetting	nil	nil	++

**Example 10**

Direct adhesion between an embryo and RBC was demonstrated using the biotinylated IgG specific for the carbohydrate antigens A,B (BiolgG<sup>A,B</sup>). In this example, two combinations of insertion were tested. In the first instance,

5      BiolgG<sup>A,B</sup> inserted mouse RBC's were shown to rosette to mouse embryos that are known to express an antigen reactive with IgG<sup>A,B</sup>. Additionally, mouse RBC's inserted with BioG and avidin only, positively adhered to mouse embryos sensitised (coated) with BiolgG<sup>A,B</sup>.

10     Mouse RBCs were inserted with BioG/Av and BioG/Av/BiolgG<sup>A,B</sup> using the following method:

1. 5µl of BioG (50mg/ml) was added to 500µl of 10% mouse RBCs in PBS (final conc. 5µg/µl of packed RBCs) and incubated on a mixer at 37°C for 1 hour. The cells were washed 3x in PBS and resuspended to 500µl.
- 15     2. 50µl of 1mg/ml avidin was added to the BioG inserted RBC solution (final conc. avidin 0.1mg/ml) and incubated on a mixer at 37°C for 1 hour. The cells were washed 3x in PBS and resuspended to give a 10% solution of RBCs. These BioG/Av inserted cells were used to react with embryo's sensitised with BiolgG<sup>A,B</sup>
- 20     3. A 100µl aliquot of BioG/Av inserted RBCs was mixed with 50µl of BiolgG<sup>A,B</sup> (10µg/10µl of packed RBCs) and incubated on a mixer at 37°C for 1 hour. The cells were washed 3x with PBS ready for the rosetting with the embryos. These BioG/Av/BiolgG<sup>A,B</sup> inserted cells were used to react directly with embryos.

25     Mouse embryos were sensitised with IgG<sup>A,B</sup> using the following method:

1. ZF and ZI day-3.5 embryos were incubated in a microdrop of 25µl of M2 media and 25µl of BiolgG<sup>A,B</sup> (final conc. 0.1mg/ml) for 1 hour at room temperature.
- 30     2. These BiolgG<sup>A,B</sup> sensitised embryos were washed 2x in M2 media and placed in a fresh well of M2 media ready for rosetting by exposure to the BioG/Av inserted mouse RBCs.

The results are outlined in Table 8.

5 **Table 8. Embryo BiolgG<sup>A,B</sup> rosette experiment. Group 1 ZF embryos rosette with BioG/Av/BiolgG<sup>A,B</sup> mouse RBCs. Group 2 ZF and ZI embryos sensitised with BiolgG<sup>A,B</sup> rosette with BioG/Av transformed RBCs. Group 3 embryos represent a negative control and fail to rosette with BioG/Av transformed RBCs.**

	Experimental Group		
	1	2	3
mRBCs configuration	BioG/Av/ BiolgG <sup>A,B</sup>	BioG/Av	BioG/Av
embryo configuration	untreated	BiolgG <sup>A,B</sup> treated	untreated
ZF binding	+++	+++	-
ZI binding	-	++	-

10 A grade from nil to 4+ was allocated to each group of embryos:

- nil no binding
- +<10 RBCs
- ++ 10-20 RBCs
- ++++ >50 RBCs

15

#### Example 11

The ability of modified embryos to adhere (through an immunological bridge) to antigens on other cell types was tested. In this example, the adhesion molecule 20 was classified as biotinylated non-specific IgG and anti IgG [BiolgG+anti-IgG] which was conjugated in a third step to the inserted molecules BioG and avidin, on the cell membranes and zona pellucida of murine embryos. To confirm the complete insertion of this complex, IgG sensitised RBCs were allowed to rosette. The IgG that is attached to the anti-D sensitised RBCs is used as an antigen for 25 the adhesion molecule – thus the antibody coating on the cells essentially acts as a cell bound protein antigen. This model is considered an *indirect* demonstrative example of adhesion, because anti-IgG is required to complete the adhesive complex.

30 Insertion, conjugation and adhesion of IgG sensitised RBCs was carried out as follows:

1. Anti-D sensitised RBCs were made by incubating 400  $\mu$ l of human serum containing human anti IgG with 200  $\mu$ l of RhD+ve human RBCs for 1 hr at 37 °C. The RBCs were then washed in Celpresol and made up to a 5% solution for the rosette technique.
- 5 2. All embryos were retrieved from super-ovulated mice at the 2-cell stage and entered into the experiment either on the day of retrieval or after 48 hours of cell culture in SQC media (late morula to blastocysts stage).
3. BioG insertion was performed on both zona intact and zona free embryos with either M2 or SQC used as the insertion media.
- 10 4. The embryos then underwent a 2<sup>nd</sup> conjugation step where they were exposed to 5  $\mu$ l of avidin (1 mg/ml) in a 50  $\mu$ l of micro-drop of media for 60 minutes at 37 °C in appropriate culture conditions for each media type (i.e. CO<sub>2</sub> or atmospheric).
5. The washed embryos underwent a 3rd conjugation with 5  $\mu$ l of BioIgG (1mg/ml) in a micro-drop of media for 30 minutes at 37 °C, then washed.
- 15 6. The embryos were placed in a micro-drop consisting of 25  $\mu$ l of M2 media and 25  $\mu$ l of monoclonal anti-IgG for 30 minutes at 22 °C.
7. The treated and control embryos were washed and placed in separate drops of M2 media. A stream of either 50% anti-D sensitised RBCs or 50% untreated D +ve RBCs were gently blown over the embryos using a pulled capillary pipette attached to a syringe.
- 20 8. After 10 minutes at room temperature, the embryos were gently transferred to fresh media micro-drops using a wide bore capillary pipette (170  $\mu$ m diameter) and assessed for RBC adherence under an inverted microscope at 250x magnification through the central plane of focus. A grade from nil to 4+ was allocated to each group of embryos:
  - nil no binding
  - + <10 RBCs
  - ++ 10-20 RBCs
  - 30 ▪ ++++ >50 RBCs
- 25
- 30

The results are shown in Table 9. The adhesion of large quantities of anti-D sensitised RBCs to embryos (2-cell to blastocysts) indicates positive insertion of Bio/Av/BiolgG and demonstrates the ability of transformed embryos to adhere.

5 There was no difference in the adhesion score between M2 and SQC insertion media. The adhesion score was moderately greater in the zona intact embryos than the zona free embryos.

10 **Table 9. Adhesion scores of BioG/Av/BiolgG transformed embryos when exposed to either anti-D sensitised or untreated group D +ve RBCs. Experiment I compares the adhesion in zona intact 2-Cells when steps were carried out in M2 or SQC media. Experiment II assesses adhesion in late morula (LM) to blastocyst (blast) stage zona intact embryos. Experiment III compares adhesion in LM-blastocyst zona intact and zona free.**

15

	Stage of embryos	Zona free Y/N	Embryo treatment type	RBCs	Adherence
Expt. I	2-Cell	N	BioG/Av/BiolgG M2 media	D +ve	-
	2-Cell	N	BioG/Av/BiolgG M2 media	anti-D sensitised	+++
	2-Cell	N	BioG/Av/BiolgG SQC media	D +ve	-
	2-Cell	N	BioG/Av/BiolgG SQC media	anti-D sensitised	+++
Expt. II	LM-Blast	N	BioG/Av/BiolgG	anti-D sensitised	++++
	LM-Blast	N	BioG/Av/BiolgG	D +ve	-
	LM-Blast	N	Control untreated	anti-D sensitised	-
	LM-Blast	N	Control untreated	D +ve	-
Expt. III	LM-Blast	N	BioG/Av/BiolgG	anti-D sensitised	+++
	LM-Blast	N	Control untreated	D +ve	-
	LM-Blast	Y	BioG/Av/BiolgG	anti-D sensitised	++
	LM-Blast	Y	Control untreated	D +ve	-

**Example 12**

Carbohydrate antigens and anti-carbohydrate binding antibodies were utilised to demonstrate adhesion between embryo and endometrial cells. In this example both embryo and endometrial cells were modified with corresponding binding molecules (IgG antibodies directed against carbohydrate antigens and antibody reactive glycolipid antigens).

Two series of insertion were tested. In the first the biotinylated antibody directed against the ALe<sup>b</sup> antigen (BiolgG<sup>ALeb</sup>) was prepared (example 2) and inserted into embryo cell membranes via the BioG/avidin bridging mechanism while endometrial cell membranes were modified with the corresponding glycolipid ALe<sup>b</sup> antigen. In the second combination biotinylated antibody directed against the Le<sup>b</sup> antigen (BiolgG<sup>Leb</sup>) was inserted into the embryo cell membranes via the BioG/avidin bridge while endometrial cell membranes were modified with the Le<sup>b</sup> glycolipid antigen.

Glycolipid modified endometrial cells were shown to adhere to the antibody modified embryos.

20 Murine endometrial cells were prepared as follows;

1. A 5-10 million/ml heterogenous solution of murine endometrial cells was prepared as described in example 6.
2. Three micro-centrifuge tubes each containing 50 µl of 5-10 million/ml endometrial cells were prepared. The following reagents were added to separate tubes a) 50 µl ALe<sup>b</sup> glycolipid (5mg/ml) b) 50 µl Le<sup>b</sup> glycolipid (5mg/ml) and c) 50 µl DMEM-F12. All cells were incubated overnight at room temperature to allow the glycolipid molecules to insert.
3. The endometrial cells for the ALe<sup>b</sup> experiment were treated with a fluorescent stain by adding 10 µl of acridine orange/ethidium bromide solution to a 50 µl of endometrial cells. All cells were incubated in dark conditions at 37° C for 30 minutes. This fluorochrome staining of the

endometrial cells prior to embryo contact assists in identifying endometrial cells adhered to embryos by fluorescent microscopy.

4. The endometrial cells were washed 3 times by suspending in CMF-HBSS and centrifuging at 2000 rpm for 3 minutes.

5

Mouse zona free embryos were inserted with BioG/Av and BiolgG<sup>ALeb</sup> or BiolgG<sup>Leb</sup> using the following method:

1. Collection of super-ovulated mouse embryos on day 3.5 post coitus was performed as described in Example 16.
2. Micro-drop culture dishes were prepared with 50  $\mu$ l of M2 media overlaid with mineral oil.
3. Embryos from each mouse were placed in SQC media microdrops and incubated in a 5% CO<sub>2</sub>, 37 °C incubator overnight.
- 10 4. Embryos with zonas intact were placed in 0.25% pronase in CMF-HBSS media for 6-8 minutes until the zona had disappeared.
5. All embryos were washed 3 times in M2 media after each treatment step by placing into a fresh drop of M2 media using a pulled glass capillary tube and syringe.
- 15 6. Zona free day 4.5 experimental mouse embryos were incubated at 37°C for 1.5 hours in a 50  $\mu$ l SQC micro-drop containing 5  $\mu$ l of BioG (50mg/ml).
7. The experimental embryos underwent a second conjugation step where they were exposed to 5  $\mu$ l of avidin (1 mg/ml) in a 50  $\mu$ l micro-drop of media for 60 minutes at 37 C.
- 20 8. Finally, the experimental embryos were split into two groups. Group 1 were placed in a 50  $\mu$ l micro-drop containing 25  $\mu$ l of BiolgG<sup>ALeb</sup> at 5 mg/ml . Group 2 in a 50  $\mu$ l micro-drop containing 25  $\mu$ l of BiolgG<sup>Leb</sup> at 5 mg/ml. Embryos were incubated for 1 hour at 37°C.

BiolgG<sup>ALeb</sup> and BiolgG<sup>Leb</sup> transformed mouse embryos were subsequently immersed in the corresponding modified endometrial cells to test for attachment in a two step process.

5

1. Micro-centrifuge tubes were prepared with the following: a) acridine orange stained ALe<sup>b</sup> glycolipid modified endometrial cells into which was placed BioG/Av/BiolgG<sup>ALeb</sup> inserted embryos; b) unstained Le<sup>b</sup> glycolipid modified endometrial cells into which was placed BioG/Av/BiolgG<sup>Leb</sup> inserted embryos.
- 10 2. The tubes containing the endometrial cells and embryos were gently mixed for 30 minutes at 37°C. Contents of each micro-centrifuge tube were transferred to a 4 well culture plate.
- 15 3. Embryos were carefully removed from the wells and mounted on glass slides. Embryos were viewed under a fluorescence microscope and photographed at 200-400x magnification.

The results are outlined in Table 10

20

Table 10 . Degree of attachment of ALeb and Leb glycolipid Inserted endometrial cells to murine embryo's inserted with BioG/Av/BiolgGALeb and BioG/Av/BiolgGLeb respectively.

Modifications to embryos and endometrial cells		
	Embryo: BioG/Av/BiolgG <sup>ALeb</sup> Endometrial cells: ALe <sup>b</sup> + AcOr	Embryo: BioG/Av/BiolgG <sup>Leb</sup> Endometrial cells: Le <sup>b</sup>
Cell attachment observed in bright field	++	++
Cell attachment observed under fluorescence	+++	ND

25

AcOr = fluorochrome acridine orange

Cell attachment scoring; + = 1-4 cells, ++ = 5-10 cells per embryo, +++ > 10 cells per embryo

ND = Not Done

**Example 13.**

The adhesive properties of *Ulex europaeus* inserted mouse embryos, was confirmed by direct adhesion to group O human RBCs by rosetting. *Ulex europaeus* is a lectin that binds specifically to the carbohydrate antigen H type 2 present on the surface of group O human RBCs and in the mucus/saliva of group O individuals expressing the secretor phenotype. Adhesion of UE transformed embryos to secretor mucus was also demonstrated by the inhibition of rosetting with group O RBCs after prior exposure to the mucus.

10 Insertion and conjugation of embryos with UE was conducted as follows:

1. The zona pellucidae were removed from embryos by incubating in a 100 $\mu$ l microdrop of 0.25% pronase in M2 media at 37°C for 6 minutes, then washed 3x in M2 media.
2. Embryos were incubated in a 50 $\mu$ l microdrop of SQC media containing 5 $\mu$ l of 50mg/ml BioG (final conc. 0.2mg/ml) for 1.5 hrs at 37°C.
- 15 3. The washed embryos were incubated in a 50 $\mu$ l microdrop of SQC media containing 5 $\mu$ l of avidin 1mg/ml (final 0.1mg/ml) for 1hr at 37°C, then washed 3x in M2 media.
4. Finally the embryos were incubated in a 50 $\mu$ l microdrop of SQC media containing 25 $\mu$ l of BioUE 100 $\mu$ g/ml (final conc. 50 $\mu$ g/ml) for 40 minutes at 37°C. After washing 3x in M2 media, the embryos were placed in a fresh drop of M2 media, in preparation for RBC rosetting.
- 20 5. Group 3 and group 4 BioUE inserted embryos were incubated for 30 minutes at RT in a 50 $\mu$ l drop of a 1:10 dilution of secretor and non-secretor mucus (respectively). The embryos were placed in a fresh drop of M2 media without washing in preparation for RBC rosetting.
- 25 6. All untreated, treated and mucus pre-exposed groups of embryos, had a stream of group O RBCs gently aspirated around them. After 10 minutes incubation at RT, the embryos were carefully transferred to a fresh drop of M2 and the degree of RBC attachment was observed under an inverted microscope as described in Example 11.
- 30

The results are outlined in Table 11.

5 **Table 11.** *Ulex europaeus* transformed mouse embryo rosette and mucus inhibition experiment. Group O (H type 2 bearing) RBCs adhere to mouse embryos that are transformed with UE (Exp. group 2). This adhesion is inhibited by pre-exposure to O secretor H type 2 bearing mucus (Exp. group 3 -) but not by O non-secretor mucus (Exp. group 4) where the H type 2 antigen is absent.

	Experimental group			
	1	2	3	4
Embryo configuration	untreated	BioG/Av/BioUE	BioG/Av/BioUE	BioG/Av/BioUE
Mucus incubation	nil	nil	O secretor	O non-secretor
RBC type	O	O	O	O
Rosetting	nil	+++	nil	+++

10 Cell attachment scoring + = 1-4 cells, ++ = 5-10 cells per embryo, +++ > 10 cell per embryo

**Example 14.**

15 In this example both embryo and endometrial cells were modified with corresponding binding molecules. The biotinylated lectin *Ulex europaeus* (BioUE) was inserted into embryo cell membranes via the BioG/avidin bridging mechanism (BioG/Av/BioUE). Endometrial cell membranes were modified with glycolipid H type 2 and stained with pyronine Y. Fluorochrome staining of the 20 endometrial cells prior to embryo adhesion assists in identification of bound endometrial cells when visualised by fluorescent microscopy.

25 Modified endometrial cells were shown to adhere to UE transformed embryos. In comparison, minimal attachment on the surface of untreated mouse embryos was observed.

Endometrial cells were inserted with H type 2 glycolipid and stained with pyronine Y by the following method.

1. A 5-10 million/ml heterogeneous solution of murine endometrial cells was prepared (as per example 6).
2. Two microcentrifuge tubes were prepared each containing a 1 ml solution of 5-10M/ml endometrial cells. The cells were subsequently centrifuged at 2000rpm for 3 minutes before aliquoting the supernatant to leave 5 µl of packed endometrial cells in each tube. 100 µl of H type 2 glycolipid extracted from human group O red cell membranes (10mg/ml) was added to the experimental group of endometrial cells and 100 µl of DMEM-F12 media added to the control group of endometrial cells. All cells were incubated 10 overnight at room temperature.
3. After each treatment step the endometrial cells were washed 3 times by resuspending in CMF-HBSS media and centrifuging at 2000 rpm for 3 minutes.
4. Endometrial cells were treated with pyronine Y by adding 20 µl of pyronine Y (15µg/ml) to each microcentrifuge tube and incubating at 37°C in dark 15 conditions. The cells were thoroughly washed.

20 Mouse zona free embryos were inserted with BioG/Av and BioUE using the following method:

1. Collection of super-ovulated mouse embryos on day 3.5 post coitus was performed as described in example 16
2. Micro-drop culture dishes were prepared with 50 µl of SQC media overlaid with mineral oil.
3. Embryos were placed in SQC media microdrops in 5% CO<sub>2</sub> and incubated 25 37°C overnight.
4. Embryos with zonas intact were placed in 0.25% protease in CMF-HBSS media for 6-8 minutes until the zona had disappeared.
5. All embryos were washed 3 times in M2 media after each treatment step 30 by placing into a fresh drop of M2 media using a pulled glass capillary tube and syringe. Embryos were split into experimental and control

groups. The experimental embryos underwent the treatment outlined in steps 6-9; the control embryos were incubated in M2 media for the equivalent length of time.

6. Zona free day 4.5 mouse embryos were incubated at 37°C for 1.5 hours  
5 in a 50 µl M2 micro-drop containing 5 µl of BioG (50mg/ml).
7. The embryos underwent a second conjugation step where they were exposed to 5 µl of avidin (1 mg/ml) in a 50 µl micro-drop of media for 60 minutes at 37°C.
8. Finally, a micro-drop was prepared with 50 µl M2 and 25 µl of BioUE  
10 (1mg/ml). Experimental embryos were placed in the micro-drop and incubated in for 1 hour at 37°C.

BioUE transformed mouse embryos were subsequently immersed in the modified endometrial cells to test for attachment in a two step process.

1. A 4-well culture dish was prepared with 2 wells each containing 50 µl of modified, and stained endometrial cells. Control embryos and modified embryos were inserted into separate wells and gently mixed for 30 minutes.  
15
2. Embryos were carefully removed from the wells and mounted on glass slides. Embryos were viewed under a fluorescence microscope and  
20 photographed at 200-400 x magnification.

The results are outlined in Table 12.

**Table 12. Attachment of murine embryo's inserted with BioG/Av/BioUE to endometrial cells inserted with H type 2 glycolipids (from red cell membranes).**

5

Modifications to embryos and endometrial cells		
Embryo: BioG/Av/BioUE Endometrial cells: H type 2 + PY	Embryo: nil Endometrial cells: nil	
Attachment	++	+/-

PY = fluorochrome pyronine Y

Cell attachment scoring = + 1-4 cells, ++ = 5-10 cells, +++ > 10 cells per embryo

ND = Not Done

10

**Example 15**

The viability of murine embryos following BioG insertion treatment was confirmed by continued culture and assessment of morphological development. Eleven 2-Cell mouse embryos underwent BioG insertion with subsequent wash steps and culture in a 50  $\mu$ l micro-drop of SQC media overlaid with mineral oil. Sixteen control embryos were cultured in a separate micro-drop in the same 4-well culture dish (Nunc 176740). Forty-eight hours later there was no difference in morphology between the experimental and control embryos. All embryos had reached the expected late morula to early blastocyst stage of development.

15 Equal numbers of embryos initiated zona hatching by Day 5 of culture.

20

**Example 16**

The viability of murine embryos treated with biotinylated ganglioside (BioG) was confirmed by the presence of implantation sites and live birth of pups after embryo transfer (ET) into recipient mice. The retrieval, treatment, and transfer of embryos were carried out on the same day at the animal facility. All embryo manipulations, molecular insertions and incubations were performed in M2 HEPES buffered media on a 37°C heated microscope stage.

30

*Donor Superovulation and Embryo Retrieval*

Large and relatively predictable numbers of embryos can be collected for experiments by using fertility drugs to stimulate the ovaries of immature mice which are highly sensitised to follicle stimulating hormone (FSH).

- 5      Prepubescent (<35 day old) CBA/C57 F1 female mice were injected with 5IU of FSH (Folligon, Pharmaco, NZ) at 1700 and again 48 hours later with 5IU of human chorionic gonadotrophin (Pregnyl, Organon, NZ). Each mouse was immediately placed with a CBA male stud mouse of proven fertility and checked for a seminal plug the following morning. The donors were sacrificed by cervical dislocation on the morning of either Day 1.5 post coitus for the retrieval of 2-cell embryos or Day 3.5 for late morula to blastocysts. The uterine horns were excised from the abdomen using sterile technique and placed into a plastic petri dish where they were flushed with media to expel the embryos.
  
- 15     *Embryo BioG Insertion*  
An equal number of high quality embryos were selected from each donor flushing and pooled together for experimental and control groups. Experimental embryos were placed in a 50  $\mu$ l micro-drop of M2 media with 2.5-5  $\mu$ l of BioG (50 mg/ml) for 1-1.5 hrs at 37°C. The embryos were washed three times with M2 and placed in a micro-drop of M2 in preparation for transfer. Control embryos were processed through drops of media at the same time as experimental embryos.

*Embryo Transfer (ET)*

- 25     To obtain a receptive endometrium in recipient mice, it is necessary to create a state of pseudopregnancy by mating with a vasectomised male mouse. The act of coitus rescues the corpus luteum of ovulated follicles from demise and sustains progesterone production necessary for implantation to occur.  
Recipient CBA/C57 F1 female mice in estrus (40-120 days old), were selected from the pool of mice and placed with a vasectomised male mouse of proven sterility. The time of mating was programmed so that recipients were synchronous for 2-Cell embryos transfers or asynchronous by minus 1 day for blastocyst stage transfers. Only recipients exhibiting a clearly identified seminal plug the following morning were selected as recipients.

The recipient mice were anaesthetised with 0.8 ml of Avertin (made in-house) and an incision was made in the side of the abdomen above the hip. The fat pad above the ovary was grasped with a serrafin clamp to withdraw the oviduct and uterus outside of the body. Using a 23-28 gauge needle, a hole was made in

5 either the bursa of the ovary to expose the infundibulum for 2-Cell stage transfers, or the uterine horn for blastocyst stage transfers. Six to ten embryos were loaded (using a mouth piece) into a fire pulled and polished capillary pipette (approx. 150-170  $\mu$ m in diameter) with mineral oil and air gaps to stabilise the embryos. The pipette was inserted into the prepared needle puncture site and

10 the embryos expelled until the release of an air-gap was visible. The exposed reproductive tract was replaced into the abdominal cavity and the body wall and skin closed with suture. The mouse was identified with ear marking and observed until conscious.

15 Mice were housed singularly in cages until they were either sacrificed for identification of implantation sites or until they had given birth. The implantation (imps) and live birth (pups) rates are presented in Table 13 and 14. All recipients were kept for 3-6 months post exposure to BioG for health assessment. The offspring were maintained for breeding of one litter to assess

20 reproductive fitness in the second generation.

**Table 13. Implantation rate (imps) and live-birth (pups) outcome of BioG and control embryos. Embryos were zona intact 2-cell embryos. Each transfer represents a single recipient mouse.**

Transfer	Treatment	Number of embryos Transferred	Preg. Y/N	Number of pups or imps. (%)	Comment
I	BioG & Control	▪ BioG 6x 2-Cell ▪ Control 6x 2-Cell	Y	▪ BioG 2x (33%) ▪ Control 2x (33%)	Each group separated into separate uterine horns Sacrificed day-7 pregnancy
II	BioG & Control	▪ BioG 5x 2-Cell ▪ black mice ▪ control 5x 2-Cell ▪ grey mice	Y	Pups 5x total ▪ BioG 3x black (60%) ▪ Control 2x grey (40%)	Same uterine horn ET No noticeable difference in anatomy or growth between BioG and control mice ET mum died 1 day before weaning – ?stress
III	BioG & Control	▪ BioG 5x 2-Cell ▪ black mice ▪ Control 5x 2-Cell ▪ grey mice	Y	Pups 5x BioG 4x black (80%) Control 1x grey (20%)	Same uterine horn ET No noticeable difference in anatomy or growth between BioG and control mice
IV	Control	6x 2-Cell	Y	Pups 5x (83%)	Born 19 days post ET – normal healthy pups
V	BioG	10x 2-Cell	Y	Pups 8x (80%)	Born 18 days post ET Normal healthy pups
VI	Control	6x 2-Cell	N	-	-
VII	BioG	10x 2-Cell	N	-	Died 3 months post ET – unknown cause
VIII	BioG	10x 2-Cell	Y	Pups 8x (80%)	Born 18 days post ET Normal healthy pups
IX	BioG	7x 2-Cell	Y	Pups 6x (85%)	Born 18 days post ET Normal healthy pups
X	Control	8x 2-Cell	Y	Pups 5x (63%)	Born 18 days post ET Normal healthy pups
XI	Control	10x 2-Cell	Y	Pups 6x (60%)	Born 20 days post ET Normal healthy pups (1x runt)

**Table 14. Implantation rate (Imps %) and live-birth outcome (pups) of BioG and control embryos. Transfers were into recipient mice at the blastocyst stage zona intact. Day-3.5 embryos were transferred into day-2.5 (Expt XII-XV) or day-3.5 (Expt. XVI – XVIII) synchronised recipient mice.**

Transfer	Treatment	No. embryos Transferred	Preg Y/N	No. imps. Or pups	Comment
XII	BioG	6x blasts	Y	Imps 4x (66%)	Uterine ET day-2.5 recipient Sacrificed D10 of pregnancy
XIII	Control	6x blasts	Y	Imps 6x (100%)	Uterine ET day-2.5 recipient Sacrificed D10 of pregnancy
XIV	BioG	6x blasts	Y	Imps 4x (66%)	Uterine ET day-2.5 recipient Sacrificed D10 of pregnancy
XV	Control	8x blasts	Y	Imps 5x (63%)	Uterine ET day-2.5 recipient Sacrificed D10 of pregnancy
XVI	Control	6x blasts	Y	Pups 4x (66%)	Uterine ET day-3.5 Recipients Normal healthy pups
XVII	BioG	6x blasts	Y	Pups 3x (50%)	Uterine ET day-3.5 Recipients Normal healthy pups
XVIII	BioG	6x blasts	Y	Pups 5x (83%)	Uterine ET day-3.5 Recipients Normal healthy pups

The first indication that BioG 2-cell embryos were capable of implantation was in a recipient mouse that had 6 BioG inserted embryos replaced into one uterine horn and 6 untreated control embryos replaced into the other horn (Transfer I). An

5 inspection of the excised uteri on Day 7 of pregnancy revealed 4 implantation sites in each horn.

The second experimental evidence showed that not only were BioG 2-Cell embryos capable of implantation but they also gave rise to live healthy pups. In transfers II

10 and III, five embryos derived from a pure black strain of mice (C57 donor and stud) were inserted with BioG and replaced into the same uterine horn as five control embryos derived from a pure grey strain of mouse (CBA donor and stud). The resulting colour of the 10 offspring, combined from both recipient mothers, was 3 grey (control embryos) and 7 black (BioG) babies.

15 Further ET experiments utilising embryos at two different stages of development, 2-cell and blastocyst, revealed similar pregnancy and live birth rates between BioG embryos and untreated control embryos for both stages of development. Overall, 8 out of 9 embryo transfers of BioG embryos resulted in a pregnancy with a live birth

20 rate of 72.0%. The transfer of control embryos resulted in a pregnancy for 6 out of 7 ETs, with a 72.5% live birth rate.

In conclusion, the insertion of BioG in zona intact embryos from 2-cell to blastocyst stage does not appear to significantly impair the implantation and ongoing

25 development of the embryo to live birth of healthy pups.

**Example 17**

The viability of zona free and zona intact murine embryos, inserted with biotinylated ganglioside (BioG) and conjugated sequentially with avidin (Av) and biotinylated IgG

30 was confirmed by the birth of live pups post embryo transfer. Embryo retrieval and

transfer of blastocysts was carried out using the methodology previously described in Example 16.

The data outlined in Table 15 showed similar live birth rates were observed 5 for experimental and control treated embryos in both the ZI and ZF groups (experimental and control respectively: ZI 61% vs 33%, ZF 83% vs 71.5%). The primary aim of this series of experiments was not to compare implantation or live birth rates, hence the small numbers and subsequent lack of statistical analysis. The results do however confirm that ZI and ZF 10 embryos inserted with the complete BioG/Av/BioIgG molecule give rise to healthy live pups.

**Example 18**

The reproductive fitness of experimental offspring and the health of the offspring 15 proved to be similar to other inbred mice within the same animal facility. Offspring from embryo transfer experiments were paired in cages and allowed to breed. All pairs produced a litter within 75 days of birth. The mean size of the litter was 6.2 pups with normal appearance (Table 16).

**Table 16. Number of pups delivered in 1<sup>st</sup> litter from experimental offspring.**

20

Experimental Origin and Pair	Treatment	No. of pups in 1 <sup>st</sup> litter
Example 4 VII	BioG	8
Example 4 VIII	BioG	5
Example 4 XI	BioG	8
Example 5 I	BioG/Av/BioIgG	4
Example 5 IV	BioG/Av/BioIgG	7
Example 5 III	Control ZI	5
Example 5 V	BioG/Av/BioIgG	10
Example 5 VI	Pronase BioG/Av/BioIgG	6
Example 5 VII	Pronase BioG/Av/BioIgG	3

**Table 15. Pregnancy outcome, number of pups and live birth rate (LB% - number of pups divided by number of embryos transfer) of BioG/Av/BiolgG blastocysts (blasts.) zona intact and zona free.**

Transfer	Treatment type	No. embryos transferred	Preg. Y/N	No. pups (LB%)	Comment
I	BioG/Av/BiolgG	6x blasts zona intact	Y	Pups 5x 83%	Born 16 days post ET Normal healthy pups
II	Control	6x blasts zona intact	N	-	-
III	Control	6x blasts zona intact	Y	Pups 2x 33%	Born 16 days post ET Normal healthy pups
IV	BioG/Av/BiolgG	6x late morula zona intact	Y	Pups 3x 50%	Born 17 days post ET Normal healthy pups
V	BioG/Av/BiolgG	6x late morula zona intact	Y	Pups x3 50%	Born 17 days post ET Normal healthy pups (1x died)
VI	Pronase BioG/Av/BiolgG	6x blasts zona free	Y	Pups 6x 100%	Born 16 days post ET Normal healthy pups (1x died)
VII	Pronase BioG/Av/BiolgG	6x blasts zona free	Y	Pups 6x 100%	Born 16 days post ET Normal healthy pups
VIII	Pronase Control	6x blasts zona free	Y	Pups 5x 83%	Born 17 days post ET Normal healthy pups
IX	Pronase Control	6x blasts zona free	Y	Pups 4x 66%	Born 16 days post ET Normal healthy pups
X	Pronase BioG/Av/BiolgG	6x blasts zona free	Y	Pups 3x 50%	Born 16 days post ET Normal healthy pups

## REFERENCES

5 Blake DA, Proctor M, Johnson N, Olive D. (2002) Cleavage stage versus blastocyst stage embryo transfer in assisted conception. *The Cochrane Library*

Bovin, N. V. "[Carbohydrate-carbohydrate interaction]." *Biokhimiia*. 61.6 (1996): 968-83.

10 Edwards, R.G., Fishel, S.B., Cohen, J. et al (1986). Factors influencing the success of in-vitro fertilisation for alleviating human infertility. *J IVF & ET*, 1: 3-23.

Ertzeid, G., and Storeng, R. (2001). The impact of ovarian stimulation on implantation and fetal development in mice. *Hum Reprod* 16: 221-225.

Feichtinger, W., Barad, D., Feinman, M., et al. (1990). The use of two-component fibrin sealant for embryo transfer. *Fertil Steril* 54: 733-734.

15 Feichtinger, W., Strohmer, H., Radner, K.M., et al. (1992). The use of fibrin sealant for embryo transfer: development and clinical studies. *Hum Reprod* 7: 890-893.

Garcia, J.E., Acosta, A.A., Hsiu, J.G., et al: (1984). Advanced endometrial maturation after ovulation induction with human menopausal gonadotropin/human chorionic gonadotropin for in vitro fertilisation. *Fertil Steril* 41: 31-35.

20 Gardner, D.K., Martinez , H.R., and Lane, M. (1999). Fetal development after transfer is increased by replacing protein with the glycosaminoglycan hyaluronan for mouse embryo culture and transfer. *Hum Reprod* 14: 2575.

25 Gott, A.L, Hardy, L., Winstone, R.M.L. et al (1990). Non-invasive measurements of pyruvate and glucose uptake and lactate production by single human preimplantation embryos. *Hum Reprod* 5: 104-108.

Hakomori, S. "Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism." *Cancer Res*. 56.23 (1996): 5309-18.

30 Hurst, T., and Lancaster, P. (2001). Assisted conception Australia and New Zealand 1999 and 2000. The University of New South Wales Annual Report. 1-33

Indiveri, F., Wilson, B.S., Pellegrino, M.A. et al (1979). Detection of human histocompatibility (HLA) antigens with an indirect rosette microassay. *J Immunol Methods* 29: 101-109

35 Karlsson, K.A. (1987) Preparation of total non-acid glycolipids for overlay analysis of receptors for bacteria and viruses and for other studies. *Methods Enzymol* 138: 212-221.

Ladisch, S., Gillar, B. (1987). Isolation and purification of gangliosides from plasma. *Methods Enzymol* 138: 300-306

Lau, C., Vogel, R., Obe, G., et al. (1991). Embryologic and cytogenetic effects of ethanol on preimplantation mouse embryos in vitro. *Reprod Tox* 5: 405-410.

Ledeen, R.W., Yu, R.K., (1982). Gangliosides: structure, isolation and analysis. *Methods Enzymol* 83:

5 Mikhalkhik, E. V., S. D. Shiyan, and N. V. Bovin. "Carbohydrate-carbohydrate interaction: zymosan and beta-glucan from *Saccharomyces cerevisiae* bind mannosylated glycoconjugates." *Biochemistry (Mosc.)* 65.4 (2000): 494-501.

Noyes, R.W., Hertig, A.T., and Rock, J. (1950). Dating the endometrial biopsy. *Fertil Steril* 1: 3-25.

10 Nygren, K.G., and Andersen, A.N. (2001). Assisted reproductive technology in Europe, 1997. Results generated from European registers by ESHRE. European IVF-Monitoring Programme (EIM), for the European Society of Human Reproduction and Embryology (ESHRE). *Hum Reprod* 16: 384-391.

15 O'Shannessy, D.L. (1990). Antibodies biotinylated via sugar moieties. *Methods Enzymol* 184: 162-166

Pittaway, D.E., and Wentz, S.C. (1983). Evaluation of the exponential rise of serum estradiol concentrations in human menopausal gonadotropin induced cycles. *Fertil Steril* 40: 763-767.

20 Plachot, M. (1992). Viability of preimplantation embryos. *Baillieres clin Obst Gynaecol.* 6: 327-338

Purdum, H.E. 1999. Compositions methods and devices for embryo implantation for in vitro fertilization. *Delphion.com*. US6196965, US.

25 Rodrigues, F.A., Van Rensburg, J.H.J., De Vries, J., et al. (1988). The effect of fibrin sealant on mouse embryos. *Journal of in Vitro Fertilization and Embryo Transfer* 5: 158-160.

Ronnberg, L., Isotalo, H., Kauppila, A., et al. (1985). Clomiphene-induced changes in endometrial receptor kinetics on the day of ovum collection after ovarian stimulation: A study of cytosol and nuclear estrogen and progestin receptors and 17beta-hydroxysteroid dehydrogenase. *Ann N Y Acad Sci* 442: 408-415.

30 Simon C, Landeras J, Zuzuarregui JL, Martin JC, Remohi J, Pellicer A. (1999) Early pregnancy losses in in vitro fertilization and oocyte donation. *Fertil Steril* 72:1061-1065

35 Sjoblom, C., Hyllner, S.J., Wikland, M., et al. (2000). Superovulation increases the incidence of cell death in murine blastocysts. *ASRM Conference Abstract Book* S17.

Sneath, J.S., and Sneath, P.H. A. (1959). Adsorption of blood-group substances from serum on to red cells. *British Medical Journal* 15:154-157.

40 van Kooij, R.J., Looman, C.W., Habbema, J.D. et al (1996). Age-dependent decrease in embryo implantation rate after in vitro fertilization. *Fertil Steril* 66: 769-775.

Wang, X. et al. "Carbohydrate-carbohydrate binding of ganglioside to integrin alpha(5) modulates alpha(5)beta(1) function." *J Biol Chem* 276.11 (2001): 8436-44.

5 Yaron, Y., Botchan, A., Amit, A. et al (1994). Endometrial receptivity in the light of modern assisted reproductive technologies. *Fertil Steril*, 62: 225-323.

Zhang, F., Schmidt, W.G., Hou, Y., et al. (1992). Spontaneous incorporation of the glycosyl-phosphatidylinositol-linked protein Thy-1 into cell membranes. *Proc Natl Acad Sci USA* 89: 5231-5235.

10 Zorn, T.M., Pinhal, M.A., Nader, H.B., et al. (1995). Biosynthesis of glycosaminoglycans in the endometrium during the initial stages of pregnancy of the mouse. *Cell Mol Biol (Noisy-le-grand)* 41: 97-106.

15

20

25

30

35

## CLAIMS

## What is claimed:

5 1. A glycolipid-inserted-embryo for the preparation of an embryo modified to enhance the implantation of the embryo into the endometrium wherein:

- the embryo has a glycolipid having lipid tails inserted into a cell membrane of the embryo or into the zona pellucida of the embryo; and
- the glycolipid has been modified to incorporate a binding part wherein said binding part is adapted to enable binding to an attachment molecule.

10 2. An embryo as claimed in claim 1 wherein the glycolipid has been modified to incorporate the binding part prior to the insertion of the lipid tails into a cell membrane of the embryo or into the zona pellucida of the embryo.

15 3. An embryo modified to enhance the implantation of the embryo into the endometrium wherein:

- the embryo has an attachment molecule which is capable of attaching to the endometrium; and
- the attachment molecule is linked to the embryo by a glycolipid having lipid tails inserted into a cell membrane of the embryo or into the zona pellucida of the embryo; and
- the attachment molecule and the glycolipid have each been modified to incorporate a binding part so that the attachment molecule and the glycolipid are bound together via their respective binding parts either directly or through a bridging molecule.

20 25 4. An embryo as claimed in any one of claims 1 to 3 wherein the modification to the glycolipid is to the carbohydrate portion of the glycolipid.

5. An embryo as claimed in any one of claims 1 to 4 wherein the attachment molecule is selected from the group consisting of carbohydrates or oligosaccharides, glycolipids, glycoconjugates, proteins, peptides, acyl groups or polymers.
- 5 6. An embryo as claimed in any one of claims 1 to 5 wherein the attachment molecule is selected from the group consisting of natural or synthetic carbohydrates or oligosaccharides, proteins or peptides including poly L-lysine, antibodies, lectins, polyvinyl pyrrolidine, and functionally equivalent derivatives thereof.
- 10 7. An embryo as claimed in any one of claims 1 to 6 wherein the attachment molecule is an immunoglobulin antibody.
8. An embryo as claimed in claim 7 wherein the attachment molecule is immunoglobulin G (IgG).
- 15 9. An embryo as claimed in any one of claims 1 to 8 wherein the attachment molecule is adapted to interact with the epithelial cells of the endometrium, mucus, mucin, or other endogenous or exogenously provided component of the endometrium.
- 20 10. An embryo as claimed in any one of claims 1 to 9 wherein the attachment molecule is an endometrial attachment molecule.
- 25 11. An embryo as claimed in any one of claims 1 to 10 wherein the glycolipid is selected from the group consisting of phosphoglycerides and sphingolipids.
12. An embryo as claimed in any one of claims 1 to 11 wherein the binding part of the glycolipid and the attachment molecule are bound together by simple non-covalent binding interactions including ionic, van de Waals, water exclusion, electrostatic, hydrogen bonding or chelation binding.
- 30

13. An embryo as claimed in any one of claims 1 to 11 wherein the binding part of the glycolipid and the attachment molecule are bound together by covalent bonding.
14. An embryo as claimed in any one of claims 1 to 10 wherein the attachment molecule and the glycolipid are bound together by avidin-biotin binding.  
5
15. An embryo as claimed in claim 14 wherein the binding part of the glycolipid comprises biotin and the binding part of the attachment molecule comprises avidin.
- 10 16. An embryo as claimed in claim 14 wherein the binding part of the glycolipid comprises avidin and the binding part of the attachment molecule comprises biotin.
17. An embryo as claimed in any one of claims 1 to 11 wherein the attachment molecule and the glycolipid are bound together through a bridging molecule.  
15
18. An embryo as claimed in claim 17 wherein the bridging molecule comprises avidin and the binding part of both the attachment molecule and the glycolipid comprises biotin.
- 20 19. An embryo as claimed in claim 17 wherein the bridging molecule comprises biotin and the binding part of both the attachment molecule and the glycolipid comprises avidin.
- 25 20. An embryo as claimed in any one of claims 1 to 11 wherein the attachment molecule and the glycolipid are bound together by a chelation interaction between at least one chelator and a chelated metal ion.
21. An embryo as claimed in claim 20 wherein the binding part of both the attachment molecule and the glycolipid comprises a chelator.

22. An embryo as claimed in claim 20 or claim 21 wherein the chelator is a poly-histidine recombinant or non-recombinant protein.
23. An embryo as claimed in any one of claims 20 to 22 wherein the chelator is attached covalently to the glycolipid.
24. An embryo as claimed in any one of claims 20 to 22 wherein the chelator is attached non-covalently to the glycolipid.
- 10 25. An embryo as claimed in claim 24 wherein the chelator is attached to the glycolipid by biotin or avidin.
26. An embryo as claimed in any one of claims 20 to 25 wherein the chelated metal ion is  $\text{Co}^{2+}$ ,  $\text{Ni}^{2+}$  or  $\text{Cu}^{2+}$ .
- 15 27. An embryo as claimed in any one of claims 1 to 26 wherein the lipid tails of the glycolipid are inserted into the cell membranes of the embryo.
- 20 28. An embryo as claimed in any one of claims 1 to 26 wherein the lipid tails of the glycolipid are inserted into the zona pellucida of the embryo.
29. An embryo as claimed in any one of claims 1 to 15, 17, 18 and 20 to 28 wherein the modified glycolipid is a biotinylated glycolipid.
- 25 30. An embryo as claimed in any one of claims 1 to 29 wherein the glycolipid is a glycolipid of the ganglioside class that contains sialic acid groups, or a glycolipid of the neutral class that contains galactose.
- 30 31. An embryo as claimed in any one of claims 1 to 30 wherein the attachment molecule is a molecule that has a binding affinity for molecules on cell membranes including the mucus coat of cell membranes.

32. An embryo as claimed in claim 31 wherein the molecules on cell membranes are receptor sites and/or blood group related antigens.

5 33. An embryo as claimed in claim 31 or claim 32 wherein the cell membranes are endometrial cell membranes.

10 34. A method of preparing a glycolipid-inserted-embryo including the step of:

- contacting a glycolipid with an embryo, wherein the glycolipid has been modified to incorporate a binding part, wherein said binding part is adapted to enable binding to an attachment molecule either directly or through a bridging molecule, so that the lipid tails of the modified glycolipid insert into a cell membrane of the embryo or into the zona pellucida of the embryo.

15 35. A method of preparing a modified embryo including the steps of:

- contacting an attachment molecule with a glycolipid, wherein the attachment molecule and the glycolipid have each been modified to incorporate a binding part adapted to enable the attachment molecule and the glycolipid to bind together via their respective binding parts either directly or through a bridging molecule; and then
- contacting the attachment molecule bound to the glycolipid with an embryo so that the lipid tails of the glycolipid insert into the cell membranes of the embryo or into the zona pellucida of the embryo.

20 36. A method of preparing a modified embryo including the steps:

- contacting a glycolipid with an embryo wherein the glycolipid has been modified to incorporate a binding part, wherein said binding part is adapted to enable binding to an attachment molecule either directly or through a bridging molecule, so that the lipid tails of the glycolipid insert into a cell membrane of the embryo or into the zona pellucida of the embryo to provide a glycolipid-inserted-embryo; and then

25

30

- contacting the glycolipid-inserted-embryo with an attachment molecule, wherein the attachment molecule has been modified to incorporate a binding part adapted to enable binding to the binding part of the glycolipid either directly or through a bridging molecule.

5

37. A method as claimed in any one of claims 34 to 36 wherein the attachment molecule is selected from the group consisting of carbohydrates or oligosaccharides, glycolipids, glycoconjugates, proteins, peptides, acyl groups or polymers.

10 38. A method as claimed in any one of claims 34 to 37 wherein the attachment molecule is selected from the group consisting of natural or synthetic carbohydrates or oligosaccharides, proteins or peptides including poly L-lysine, antibodies, lectins, polyvinyl pyrrolidine, and functionally equivalent derivatives thereof.

15 39. A method as claimed in any one of claims 34 to 38 wherein the attachment molecule is an immunoglobulin antibody.

40. A method as claimed in claim 39 wherein the attachment molecule is immunoglobulin G (IgG).

20

41. A method as claimed in any one of claims 34 to 41 wherein the attachment molecule is adapted to interact with the epithelial cells of the endometrium, mucus, mucin, or other endogenous or exogenously provided component of the endometrium.

25

42. A method as claimed in any one of claims 34 to 41 wherein the attachment molecule is an endometrial attachment molecule.

30

43. A method as claimed in any one of claims 34 to 42 wherein the glycolipid is selected from the group consisting of phosphoglycerides and sphingolipids.

44. A method as claimed in any one of claims 34 to 43 wherein the attachment molecule and the glycolipid are bound together by simple non-covalent binding interactions including ionic, van de Waals, water exclusion, electrostatic, hydrogen bonding or chelation binding.

5

45. A method as claimed in any one of claims 34 to 43 wherein the attachment molecule and the glycolipid are bound together by covalent bonding.

10 46. A method as claimed in any one of claims 34 to 43 wherein the attachment molecule and the glycolipid are bound together by avidin-biotin binding.

47. A method as claimed in claim 46 wherein the binding part of the glycolipid comprises biotin and the binding part of the attachment molecule comprises avidin.

15 48. A method as claimed in claim 46 wherein the binding part of the glycolipid comprises avidin and the binding part of the attachment molecule comprises biotin.

49. A method as claimed in any one of claims 34 to 44 wherein the attachment molecule and the glycolipid are bound together through a bridging molecule.

20

50. A method as claimed in claim 49 wherein the bridging molecule comprises avidin and the binding part of both the attachment molecule and the glycolipid comprises biotin.

25 51. A method as claimed in claim 49 wherein the bridging molecule comprises biotin and the binding part of both the attachment molecule and the glycolipid comprises avidin.

30 52. A method as claimed in any one of claims 34 to 44 wherein the attachment molecule and the glycolipid are bound together by a chelation interaction between at least one chelator and a chelated metal ion.

53. A method as claimed in claim 52 wherein the binding part of both the attachment molecule and the glycolipid is a chelator.

5 54. A method as claimed in claim 52 or claim 53 wherein the chelator is a poly-histidine recombinant or non-recombinant protein.

55. A method as claimed in any one of claims 52 to 54 wherein the chelator is attached covalently to the glycolipid.

10 56. A method as claimed in any one of claims 52 to 54 wherein the chelator is attached non-covalently to the glycolipid.

15 57. A method as claimed in claim 56 wherein the chelator is attached to the glycolipid via biotin or avidin.

58. A method as claimed in any one of claims 52 to 57 wherein the chelated metal ion is  $\text{Co}^{2+}$ ,  $\text{Ni}^{2+}$  or  $\text{Cu}^{2+}$ .

20 59. A method as claimed in any one of claims 34 to 58 wherein the lipid tails of the glycolipid are inserted into the cell membranes of the embryo.

60. A method as claimed in any one of claims 34 to 58 wherein the lipid tails of the glycolipid are inserted into the zona pellucida of the embryo.

25 61. A method as claimed in any one of claims 34 to 47, 49, 50 and 52 to 60 wherein the modified glycolipid is a biotinylated glycolipid.

30 62. A method as claimed in any one of claims 34 to 61 wherein the glycolipid is a glycolipid of the ganglioside class that contains sialic acid groups, or a glycolipid of the neutral class that contains galactose.

63. A method as claimed in any one of claims 34 to 62 wherein the attachment molecule is a molecule that has a binding affinity for molecules on cell membranes including the mucus coat of cell membranes.

5

64. A method as claimed in claim 63 wherein the molecules on cell membranes are receptor sites and/or blood group related antigens.

10 65. A method as claimed in claim 63 or claim 64 wherein the cell membranes are endometrial.

66. A method of enhancing the implantation of an embryo into the endometrium of an animal including the steps:

15 • preparing a modified embryo according to the method of any one of claims 35 to 65; and

• transferring the modified embryo to the uterus of the animal.

67. A method as claimed in claim 66 including the step:

20 • introducing a component with which the attachment molecule will interact into the uterus of the animal so that the component becomes localised to the endometrium.

68. A method as claimed in claim 66 or claim 67 wherein the animal is a human or domesticated animal.

25

69. A method as claimed in claim 66 or claim 67 wherein the modified embryo is prepared from a species, hybrid or variety of animal different from the species, hybrid or variety of animal of the uterus.

30 70. A glycolipid-attachment molecule construct for use in enhancing the implantation of an embryo into the endometrium of an animal comprising a glycolipid

modified to incorporate a binding part and an attachment molecule modified to incorporate a binding part wherein the respective binding parts are adapted to enable the modified glycolipid and the modified attachment molecule to bind to each other either directly or indirectly through a bridging molecule.

5

71. A construct as claimed in any one of claims 70 wherein the modification to the glycolipid is to the carbohydrate portion of the glycolipid.

10 72. A construct as claimed in claims 70 or 71 wherein the attachment molecule is selected from the group consisting of carbohydrates or oligosaccharides, glycolipids, glycoconjugates, proteins, peptides, acyl groups or polymers.

15 73. A construct as claimed in any one of claims 70 to 72 wherein the attachment molecule is selected from the group consisting of natural or synthetic carbohydrates or oligosaccharides, proteins or peptides including poly L-lysine, antibodies, lectins, polyvinyl pyrrolidine, and functionally equivalent derivatives thereof.

74. A construct as claimed in any one of claims 70 to 73 wherein the attachment molecule is an immunoglobulin.

20

75. A construct as claimed in claim 74 wherein the attachment molecule is immunoglobulin G (IgG).

25 76. A construct as claimed in any one of claims 70 to 75 wherein the attachment molecule is adapted to interact with the epithelial cells of the endometrium, mucus, mucin, or other endogenous or exogenously provided component of mucus.

77. A construct as claimed in any one of claims 70 to 76 wherein the attachment molecule is an endometrial attachment molecule.

30

78. A construct as claimed in any one of claims 70 to 77 wherein the glycolipid is selected from the group consisting of phosphoglycerides and sphingolipids.

79. A construct as claimed in any one of claims 70 to 78 wherein the attachment 5 molecule and the glycolipid are bound together by simple non-covalent binding interactions including ionic, van de Waals, water exclusion, electrostatic, hydrogen bonding and chelation binding.

80. A construct as claimed in any one of claims 70 to 79 wherein the attachment 10 molecule and the glycolipid are bound together by covalent bonding.

81. A construct as claimed in any one of claims 70 to 79 wherein the attachment molecule and the glycolipid are bound together by avidin-biotin binding.

82. A construct as claimed in claim 81 wherein the binding part of the glycolipid 15 comprises biotin and the binding part of the attachment molecule comprises avidin.

83. A construct as claimed in claim 81 wherein the binding part of the glycolipid comprises avidin and the binding part of the attachment molecule comprises biotin.

84. A construct as claimed in any one of claims 70 to 80 wherein the attachment 20 molecule and the glycolipid are bound together through a bridging molecule.

85. A construct as claimed in claim 84 wherein the bridging molecule comprises 25 avidin and the binding part of both the attachment molecule and the glycolipid comprises biotin.

86. A construct as claimed in claim 84 wherein the bridging molecule comprises 30 biotin and the binding part of both the attachment molecule and the glycolipid comprises avidin.

87. A construct as claimed in any one of claims 70 to 79 wherein the attachment molecule and the glycolipid are bound together by a chelation interaction between at least one chelator and a chelated metal ion.

5 88. A construct as claimed in claim 87 wherein the binding part of both the attachment molecule and the glycolipid comprises a chelator.

89. A construct as claimed in claim 87 or claim 88 wherein the chelator is a poly-histidine recombinant protein.

10 90. A construct as claimed in any one of claims 87 to 89 wherein the chelator is attached covalently to the glycolipid.

91. A construct as claimed in any one of claims 87 to 89 wherein the chelator is attached non-covalently to the glycolipid.

15 92. A construct as claimed in claim 91 wherein the chelator is attached to the glycolipid via biotin or avidin.

20 93. A construct as claimed in any one of claims 87 to 92 wherein the chelated metal ion is  $\text{Co}^{2+}$ ,  $\text{Ni}^{2+}$  or  $\text{Cu}^{2+}$ .

25 94. A construct as claimed in any one of claims 70 to 82, 84, 85 and 87 to 93 wherein the glycolipid modified to incorporate a binding part is a biotinylated glycolipid.

95. A construct as claimed in any one of claims 70 to 94 wherein the glycolipid is a glycolipid of the ganglioside class that contains sialic acid groups, or a glycolipid of the neutral class that contains galactose.

30

96. A construct as claimed in any one of claims 70 to 95 wherein the attachment molecule is a molecule that has a binding affinity for molecules on cell membranes including the mucus coat of cell membranes.

5 97. A construct as claimed in claim 96 wherein the molecules on cell membranes are receptor sites and/or blood group related antigens.

98. A construct as claimed in claim 96 or 97 wherein the cell membranes are endometrial.

10 99. A construct as claimed in any one of claims 70 to 97 wherein the attachment molecule is a molecule that has a binding affinity for molecules on embryo cell membranes or the zona pelludica.

15 100. A method of enhancing the implantation of an embryo into the endometrium of an animal including the steps of:

- introducing a construct as claimed in claim 99 into the uterus of the animal so that the construct becomes localised to the endometrium; and then
- transferring the embryo to the uterus of the animal.

20 101. A kit for use in enhancing the implantation of an embryo of an animal comprising one or more preparations of a glycolipid-attachment molecule construct as claimed in any one of claims 70 to 99.







Figure 1




**Figure 2**




**Figure 3**




**Figure 4a**




**Figure 4b**




**Figure 4c**




**Figure 5**




**Figure 6**




**Figure 7**




**Figure 8a**



**Figure 8b**



**Figure 9a**



**Figure 9b**

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ03/00059

<b>A. CLASSIFICATION OF SUBJECT MATTER</b>		
Int. Cl. <sup>7</sup> : C12N 5/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) SEE BELOW		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched SEE BELOW		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN (WPIDS; Medline): embryo; implant?; glycolipid		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9905255, A (North-Eastern University) 04.02.1999; see claims	1-101
A	Mol Hum Reprod 2, pp 52-9 (1996) Taylor et al "Complement-binding proteins are strongly expressed by human preimplantation blastocysts and cumulus cells as well as gametes"	
X	J Reprod Fert 95, pp 813-823 (1992) Zhu et al "Glycosphingolipids of rabbit endometrium and their changes during pregnancy"	1-101
<input type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"B" earlier application or patent but published on or after the international filing date</p> <p>"C" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"D" document referring to an oral disclosure, use, exhibition or other means</p> <p>"E" document published prior to the international filing date but later than the priority date claimed</p> <p>"F" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"G" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"H" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"I" document member of the same patent family</p>		
Date of the actual completion of the international search 27 June 2003		Date of mailing of the international search report - 8 JUL 2003
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaaustralia.gov.au Facsimile No. (02) 6285 3929		Authorized officer  MADHU K. JOGIA Telephone No : (02) 6283 2512

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

**PCT/NZ03/00059**

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report	Patent Family Member
WO 9905255	AU 85053/98
END OF ANNEX	